Epstein-Barr virus gp350 role in T-cell tropism and protection against infection: implications for an EBV vaccine by Smith, Nicholas A.
EPSTEIN-BARR VIRUS GP350 ROLE IN T-CELL TROPISM AND PROTECTION 
AGAINST INFECTION: IMPLICATIONS FOR AN EBV VACCINE 
by 
NICHOLAS ARTHUR SMITH 









A thesis submitted to the  
Faculty of the Graduate School of the  
University of Colorado in partial fulfillment 
of the requirements for the degree of 










This thesis for the Doctor of Philosophy degree by 
Nicholas Arthur Smith 







Raul Torres, Chair 




Rosemary Rochford, Advisor 
 
 
Date: December 14, 2018 
 
 
	   iii	  
Smith, Nicholas Arthur (PhD, Immunology) 
Epstein-Barr Virus gp350 Role in T-cell Tropism and Protection Against Infection: 
Implications for an EBV Vaccine 
Thesis directed by Professor Rosemary Rochford 
Abstract 
 Epstein-Barr virus (EBV) is a human specific gammaherpesvirus that infects greater 
than 95% of the world’s population. EBV does not typically cause severe disease, however in 
some cases it is associated with malignancies of the three cell types that it infects; B-cells, 
epithelial cells, and T-cells. There are two main strains of EBV, EBV type 1 (EBV-1) and 
EBV type 2 (EBV-2), differentiated both genetically and phenotypically, including 
differences I describe here in the viral glycoprotein gp350. Recently, we have described the 
ability for EBV-2 to infect T-cells, both in vitro and in vivo, giving us the first model system 
to study T-cell infection. In this dissertation, I show that interactions between gp350 and the 
cellular receptor CD21 facilitate T-cell infection. Furthermore, I define the viral gene 
expression that occurs within 24 hours of infection of T-cells, including identifying virion 
associated RNAs that may contribute to infection of both T-cells and B-cells. I have also 
analyzed the humoral immune response following asymptomatic infection in infants from an 
area in which both EBV-1 and EBV-2 are prevalent. Importantly, there was reduced anti-
gp350 IgA response in infants with co-infection of both EBV types, suggesting a role for 
anti-gp350 IgA antibodies in protection against co-infection.  Furthermore, upon testing the 
ability for plasma antibodies to prevent EBV-2 infection, I observed an enhancement of T-
cell infection after incubation of virus with plasma from both EBV-1 and EBV-2 infected 
persons, through still undefined mechanisms. Overall, these studies suggest the need for an 
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EBV vaccine that takes into account genetic variation between EBV-1 and EBV-2 and 
generates an IgA response against gp350. 
The form and content of this abstract are approved. I recommend its publication. 
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CHAPTER I 
 INTRODUCTION 
EBV associated diseases 
Epstein-Barr virus (EBV) is a human gammaherpesvirus that infects greater than 95% 
of the world’s population [1]. EBV has a large double stranded DNA genome of 
approximately 170kb and encodes greater than 80 genes. The majority of primary infections 
with EBV are asymptomatic. However, in about 500 of 100,000 at risk persons per year, 
EBV infection can cause the self-limiting disease called acute infectious mononucleosis 
(AIM) [2]. In addition to asymptomatic infection and AIM, EBV is classified as a group 1 
carcinogen and is associated with approximately 200,000 cancers worldwide per year [1].  
The virus itself was first discovered in 1964 from B-cell lines generated from 
Burkitt’s lymphoma [3]. Since then, EBV has been associated with other B-cell 
lymphoproliferative disorders, including Hodgkin’s lymphoma, post-transplant 
lymphoproliferative disease, and AIDS associated B-cell lymphomas [4-6] EBV has also 
been found to be associated with epithelial cell cancers, including nasopharyngeal carcinoma 
(NPC) and gastric carcinoma [7, 8]. In addition to diseases of B-cells and epithelial cells, 
EBV is also associated with a number of lymphoproliferative diseases and cancers of the less 
well understood infection of T-cells. These include T-cell chronic active EBV, peripheral T-
cell lymphomas, extranodal NK/T-cell lymphomas, hemophagocytic lymphohistiocytosis, 
and hydroa vacciniforme-like lymphoma [9-14] In contrast to B-cells and epithelial cell 
diseases, which have been extensively studied, the role of EBV in T-cell diseases has been 
limited due to the lack of an in vitro infection model and limited examples of infection of T-
cells in healthy carriers.  
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EBV in vivo life cycle 
Classically, EBV is transmitted through saliva or as more recently shown in a Kenyan 
population, breast-milk[15, 16]. It has been proposed that primary infection can occur within 
epithelial cells in the oropharynx, in which the virus undergoes lytic replication to produce 
infectious virions [17]. These virions will then latently infect naïve tonsillar B-cells. It is also 
thought that the virus can traverse the epithelial cell layer and directly infect naïve B-cells, 
without epithelial cell replication [18]. Thorley-Lawson developed a model for the in vivo 
life cycle of EBV which is summarized in figure 1 [19]. Upon infection of naïve B-cells, the 
virus will express a latency III pattern, also termed the growth program, in which the latent 
genes Epstein-Barr nuclear antigen (EBNA) -1, EBNA-2, EBNA-3A-C, latent membrane 
protein (LMP) -1, and LMP-2 are expressed [20]. This drives the cell into a germinal center 
reaction and latent gene expression is repressed to latency II, also known as the default 
program [21]. This includes expression of EBNA-1, LMP-1, and LMP-2. The cells further 
differentiate into memory B-cells [22]. When the memory B-cell is dividing, the virus will 
express a latency I pattern, in which only EBNA-1 is expressed [23]. In a quiescent memory 
B-cell, a latency 0 pattern, or true latency, is observed, in which no viral genes are expressed 
[24]. If an infected memory B-cell differentiates into a plasma cell, the virus will reactivate 
and produce infectious virions [25]. These virions will go on to infect additional naïve B-
cells, epithelial cells, or be shed to infect a new person. This cycle of latency and reactivation 
occurs throughout the life of the infected host.  
The in vivo life cycle of EBV, which drives an infected naïve B-cell towards a 
memory B-cell phenotype, is a subversion of the normal B-cell processes following 
interaction with cognate antigen. This classical B-cell pathway in response to activation by 
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antigen is described in figure 2 [26]. B-cells detect their cognate antigen through their B-cell 
receptor (BCR), which signals through immunoreceptor tyrosine-based activation motifs 
(ITAM) [27]. These same motifs are present on the viral protein LMP-2, which constitutively 
signals and mimics BCR engagement [28]. Following this interaction the BCR is internalized 
and antigen is processed and presented on major histocompatibility complex (MHC) as 
peptides. Professional antigen presenting cells, such as dendritic cells, present antigen 
peptides loaded on MHC to activate antigen specific CD4+ T-cells through their T-cell 
receptor (TCR). Following activation of antigen specific B-cells and T-cells, these cells 
interact through MHC and peptide / TCR and CD40 / CD40 ligand (CD40L) interactions to 
fully activate the B-cell [29]. CD40 signaling drives a number of molecular pathways 
involved in B-cell survival and maturation [30].  EBV also mimics this signaling molecule 
with the viral LMP-1, which is a constitutively active CD40 mimic and drives survival and 
differentiation of an infected naïve B-cells[31, 32]. This also moves an antigen activated B-
cell into the dark zone of the germinal center, where it proliferates and undergoes somatic 
hypermutation (SHM) [33]. SHM is a process which drives mutations in the BCR locus, with 
the goal of increasing the affinity and avidity of BCR / antigen interactions. To determine the 
outcome of SHM, the B-cell moves into the light zone of the germinal center and interacts 
with follicular dendritic cells presenting antigen for the BCR and T-cells through MHC and 
peptide / TCR and CD40 / CD40L interactions [34]. If the BCR and CD40 provide a weak 
signal because of non-ideal BCR interactions, the B-cell undergoes apoptosis. If there is a 
stronger signal induced due to effective SHM, producing stronger BCR interactions, the B-
cell will either recirculate through the dark zone for further SHM and proliferation or 
differentiate into a memory B-cell or antibody secreting plasma cell. However, since LMP-1 
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and LMP-2 provide these required signals, EBV can drive B-cells without an ideal BCR 
through the germinal center and prevent apoptosis [35]. This process is critical to the 
establishment of latency within an EBV-infected memory B-cell.  
Persistence has been modeled in vitro through the ability for EBV to immortalize 
primary B-cells and generate lymphoblastoid cell-lines (LCLs). LCLs will sustain a latency 
III pattern of expression upon immortalization [36] Depending on the cell-line, 
approximately 1-5% of the cells are undergoing lytic viral gene expression [36]. 
EBV strain variation 
Genotype 
This dissertation largely focuses on the second, less common strain of EBV, EBV 
type 2 (EBV-2). EBV-2 is genetically and phenotypically distinct from the more common 
strain EBV type 1 (EBV-1). The primary genetic differences between these two types have 
been shown to be within the EBNA-2, EBNA-3A, and EBNA-3C genes [37-43]. Based on 
deletion and insertion mutations between these strains, PCR based methods have been 
designed to distinguish these virus types. More recently, differences in the BZLF1 promoter 
Zp and the viral glycoprotein gp350 have been shown to be distinct between EBV-1 and 
EBV-2 strains [44]. However, the Zp variant associated with EBV-2 can be found in EBV-1 
strains [45]. Some linkage to EBV type has been described for EBNA1 and LMP-1, though 
not as strictly associated as the differences in other genes [44]. The phenotypic role for 
differences in these genes have only been minimally studied.  
Phenotype 
Historically, the major phenotypic difference between EBV-1 and EBV-2, in vitro, is 
the impaired ability for EBV-2 to immortalize B-cells [38, 41]. We have more recently 
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shown that EBV-2 has the unique ability to infect T-cells, both in vitro and in vivo [46, 47]. 
These functional differences are likely due to the genetic differences in the genes mentioned 
above. 
The majority of mechanistic studies for EBV have generalized results using strictly 
EBV-1 isolates. However, differences in EBNA-2 have been shown to be critical for the 
immortalization defect of EBV-2. For instance, the EBV-2 EBNA-2 gene has been shown to 
induce some cellular genes at a lower level than EBV-1, which may play a role in the 
transformation differences [48]. This same study also showed that the EBV-2 EBNA-2 has a 
reduced ability to induce expression of the viral gene LMP-1. Furthermore, the diminished 
immortalization capacity of EBV-2 has been attributed to a single amino acid change from 
EBV-1 in EBNA-2 [49]. However, the phenotypic differences caused by differences in 
EBNA-3A and EBNA-3C have not been explored. Despite the limitations to immortalize B-
cells in vitro and apparent deficiencies at establishing latency, EBV-2 does have the ability to 
persist in some populations.  
Epidemiology 
EBV-1 is widely prevalent, being the most predominant strain in the world. However, 
there are particular regions where EBV-2 can be found at a high frequency. The geographic 
distribution of the two EBV types are summarized from numerous studies in Figure 3A [50-
77]. In general, EBV-2 is most prevalent in the healthy populations in areas of Sub-Saharan 
Africa and Papua New Guinea (Figure 3A). Infection with EBV-2 is also more prevalent in 
people infected with HIV, compared to the healthy global population (Figure 3B). This 
phenomenon is consistent even in areas where EBV-2 is not common [69]. It is still unclear, 
however, what allows EBV-2 to persist in particular populations. 
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EBV and T-cells 
 EBV was first proposed to infect T-cells when the EBV genome was detected by in 
situ hybridization in tumor tissues of patients with T-cell lymphomas [78]. Since then, it has 
been characterized in other T-cell diseases, including chronic active EBV, hemophagocytic 
lymphohistiocytosis, and hydroa vaccinoforme-like lymphoma [9, 10, 13, 14]. Outside of 
EBV+ T-cell driven diseases, EBV infection has also been detected in peripheral CD4+ and 
CD8+ T-cells of HIV+ children [79]. Until recently, only in vitro infection of immature 
thymocytes has been described [80]. This infection induced proliferation of thymocytes and 
expression of EBNA-1 protein. Another group described expression of BZLF1 transcripts 
following thymocyte infection [81]. Infection caused an expansion of CD4/CD8 double 
positive thymocytes, which was further enhanced by IL-2 and blocked by anti-IL2R 
antibodies and cyclosporine A [82]. However, the limited descriptions of T-cell infection 
with EBV, both in vitro and in vivo, have hampered research into the etiology of these 
diseases.  
Recently, we have described the unique ability for EBV-2 to infect mature, peripheral 
T-cells, in vitro [47]. The infection of T-cells by EBV-2 induces proliferation, activation, 
prolonged survival, and expression of various cytokines, including RANTES, MIP1α, 
MIP1β, and IL-8. This infection has a preference for CD8+ T-cells, compared to CD4+ T-
cells, though both cell types are infected. We defined this as a latent infection, with a latency 
III pattern, as we could detect EBNA-1, EBNA-2, LMP-1, and LMP-2 protein expression 
beginning at 1 day post infection. This pattern of expression remains through 12 days post 
infection. This is markedly different than what is observed following B-cell infection, in 
which latency III is not achieved until 7-14 days post infection [36]. Furthermore, increase in 
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viral load observed over time was not inhibited by acyclovir or phosphonoacetic acid, two 
drugs known to block gammaherpesvirus lytic replication [47].  
The infection of mature T-cells by EBV-2 has some different characteristics than 
thymocyte infection. For instance, the proliferation of thymocytes was induced by the EBV-1 
strain B95.8 but not by the EBV-2 strain, P3HR1, while mature T-cell infection was specific 
for EBV-2 [81]. Also, EBV-2 induced proliferation of mature T-cells is not blocked by 
cyclosporine A, as seen in thymocyte infection [47, 82]. This suggests that the infection of 
mature T-cells may be unique to the biology of EBV-2 and distinct from thymocyte 
infection.  
Not only does EBV-2 infect T-cells in vitro, we have also shown that EBV-2 can 
infect T-cells of healthy children from EBV-2 prevalent region in Kenya [46]. In this study, 
we showed in all six of the EBV-2 infected infants, EBV-2 DNA was found in isolated T-
cells. As hypothesized, we could not detect any EBV DNA in T-cells of EBV-1 infected 
infants. Interestingly, in the one EBV-1 and EBV-2 co-infected participant, there was EBV-2 
DNA found in the isolated T-cells, but no EBV-1 DNA. This supports our hypothesis that T-
cell infection is part of the normal biology of EBV-2. This also raises the question as to what 
the role T-cells could be in the in-vivo life cycle of EBV-2.  
Cellular entry glycoproteins and functions 
Part of this dissertation focuses on the entry of EBV-2 into T-cells. The mechanisms 
that EBV uses to infect both B-cells and epithelial cells have been extensively studied. 
However, these two methods are unique from one another. The critical processes involved in 
B-cell and epithelial cell infection are summarized in figure 4a and 4b, respectively. B-cell 
infection requires the viral glycoproteins gp350, gp42, gHgL, and gB, while the infection of 
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epithelial cells only require the use of gHgL and gB. The cellular receptors for these 
glycoproteins and their role in this process are described below.  
gp350 
B-cell entry by EBV has been extensively studied. This process begins with the viral 
gp350, the most abundant glycoprotein on the surface of the EBV virion, binding to the 
cellular CD21 orCD35, complement receptor 2 and 1, respectively [83-88]. gp350/CD21 
interactions also initiate endocytosis of the virion [89]. gp350 deficient viruses have much 
reduced ability to bind and infect B-cells, in vitro [90]. However, gp350 is dispensable for 
fusion in cell-cell fusion assays [91]. CD35 has been shown to be important for B-cell 
infection when CD21 is knocked-out in vitro [88]. Importantly, gp350 is not involved in 
entry into epithelial cells. Interestingly, monoclonal antibodies against gp350 have actually 
been shown to enhance epithelial cell infection in vitro [92, 93]. The infection of immature 
thymocytes has been shown to be blocked by antibodies against CD21 and gp350 [80]. 
However, this has not been explored further.  
gp42 
The second step in B-cell infection is an interaction between another EBV 
glycoprotein, gp42, in a trimeric complex with gH and gL, and the cellular receptor HLA 
Class II (DR, DP, or DQ) [94-96]. Viruses lacking gp42 can bind, but cannot infect B-cells 
[97, 98]. Upon binding HLA-Class II, gp42 undergoes two conformational changes, one in 
the amino terminus and another that widens a previously defined hydrophobic pocket [99-
103]. These conformational changes have been hypothesized to allow access of the plasma 
membrane to the core fusion machinery of EBV, gH, gL, and gB. Like gp350, gp42 is 
dispensable for epithelial cell infection. 
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Interestingly, EBV shed in saliva has high-levels of gp42, compared to LCL derived 
virus from the same person [104].  gp42 low virions are more efficient at infecting epithelial 
cells compared to gp42 high virions produced from epithelial cells, and vice versa [105]. It 
has been proposed that when gp42 is trafficking to the cellular membrane upon egress, gp42 
interacts with HLA-Class II within the cell. This causes a proportion of these complexes to 
be targeted for degradation. This does not occur within epithelial cells, as HLA-Class II is 
not expressed. Therefore, gp42 has been hypothesized as important as a tropism switch 
between these two cell types.  
gHgL 
Fusion is mediated by three glycoproteins, gH, gL, and gB, which are the conserved 
core fusion machinery with orthologs in all herpesviruses [106]. gL is involved in folding 
and chaperoning gH to the cell surface upon egress [107]. The gHgL complex is not a direct 
fusogen, but has instead been hypothesized to regulate the fusogen gB [108-111]. gHgL are 
required for infection of both B-cells and epithelial cells as gHgL deficient virus are unable 
to infect both cell types [97, 112-114]. However, within the gp42gHgL complex that is 
required for B-cell infection, gHgL do not bind a cellular receptor directly. Instead, the gHgL 
complex plays a role in promoting fusion following gp42 interaction with HLA class II [108, 
109] 
In epithelial cell infection, the gHgL complex mediates the initial attachment event 
and helps to promote fusion with gB. It has been shown that gH, through its KGD integrin 
binding motif interacts with αvβ5, αvβ6, or αvβ8 integrins [115, 116]. This interaction 
triggers a conformational change and allows for fusion [116, 117]. More recently, gHgL has 
been shown to bind ephrin A2 receptor on the surface of epithelial cells [118, 119]. 
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Attachment and fusion occur at the viral membrane of epithelial cells, not within an 
endosome as shown in B-cell infection [120].  
gB 
The viral glycoprotein gB is required for infection of both epithelial cells and B-cells 
and has been shown to be the fusogen of EBV [91]. gB is a class III viral fusion protein and 
initially exists as a trimer [121, 122]. There is no known receptor for gB on B-cells. It is 
hypothesized that conformation changes, mediated by gHgL, allow for gB, through its two 
fusion loops, to fuse the viral membrane with the cellular membrane. Mutations in these 
fusion loops reduce the ability to fuse [123]. Furthermore, viruses deleted for gB are able to 
bind and enter endocytic vesicle in B-cells, but are not able to fuse and enter [124]. Recently, 
gB has been shown to interact with the cellular neuropilin-1 receptor on nasopharyngeal 
epithelial cells [125]. This occurs through a CendR motif that is cleaved by furin following 
the previously described interactions of the gHgL complex. This is the first example of a 
receptor for gB. However, the expression of neuropilin-1 is relatively low on B-cells and its 
role in B-cell infection has not been explored. 
BRLF2 
The viral glycoprotein BRLF2 has also been shown to be involved in binding of the 
virion to B-cells and epithelial cells through interaction with β1 integrins. It has been shown 
that tonsillar memory B-cells that express β1 integrins are more efficiently infected [126]. 
The same has been shown for polarized tongue and nasopharyngeal epithelial cells [127]. 
However, in neither case has this interaction been shown to be required for infection. 
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Key EBV gene functions 
Similar to observations of EBV infection of B-cells in vivo, there is a well described 
pattern of EBV gene expression following infection of B-cells in vitro. This in vitro infection 
ultimately culminates to development of the immortalized LCLs that express a type III 
latency, in which all latency genes are expressed. The major functions of these gene products 
are discussed below. 
LMP-1 
LMP-1 is a constitutively signaling CD40 mimic and the primary EBV oncogene [31, 
32, 128]. LMP-1 activates NFκB, p38 mitogen-activated protein kinase, phosphatidylinositol 
2-kinase, and c-Jun N-terminal kinase and is required for EBV-mediated transformation 
[129-135] Through this signaling, LMP-1 induces survival, proliferation, migration, and 
immune evasion pathways within the expressing cell [136-139]. Through this signaling, 
along with LMP-2, infected B-cells are rescued from apoptosis in the germinal center and 
transition into memory cells [140]. In vivo, LMP-1 is expressed during latency III and II 
[19]. LMP-1 is not detectable, following in vitro infection of B-cells, until about 7-days post 
infection [36, 141]. It reaches peak levels of expression at approximately 14-days post 
infection and expression is sustained through immortalization and in LCLs. 
LMP-2 
LMP-2 is a constitutively active mimic of the B-cell receptor (BCR) [142]. In a study 
in which LMP-2 was expressed in T-cells, it acts as a mimic of the T-cell receptor (TCR) 
[28]. It primarily signals through the ERK/MAPK pathways [143]. LMP-2 has been shown to 
block antigen dependent signaling of B-cells and T-cells through sequestration of signaling 
molecules that interact with the immunoreceptor tyrosine-based activation motifs present on 
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LMP-2, BCRs, and TCRs [28, 144, 145]. It also reduces BCR function by preventing BCR 
recruitment to lipid rafts [146]. LMP-2 upregulates the anti-inflammatory and pro-survival 
cytokine IL-10 [147]. These functions promote B-cell growth and LMP-2 has been shown to 
have transformation ability, in vitro and in vivo [148]. However, it is not essential for in vitro 
or in vivo transformation of B-cells [149-151]. LMP-2 is required, with LMP-1, for germinal 
center survival of infected B-cells without the ideal BCR, in vivo [142]. LMP-2 is expressed 
in the same pattern as LMP-1, during latency III, and II in vivo, and beginning at around 7-
days post infection of B-cells, in vitro [19, 36]. 
EBNA-1 
EBNA-1 is a DNA binding protein that is expressed in all stages of B-cell infection, 
except latency 0, when a latently infected memory B-cell is not dividing [19, 36]. It is 
essential for latent replication, as it tethers the viral episome to the cellular chromosome 
during cell division [152-156]. EBNA-1 is also important for suppression of spontaneous 
lytic replication [157, 158]. However, once lytic infection begins, it does have role in 
promoting lytic replication.  EBNA-1 has roles in disrupting promyelocytic leukemia nuclear 
bodies which causes a reduction in p53 activation and suppression of apoptosis in response to 
DNA damage in epithelial cell tumors [157, 159]. Furthermore, EBNA-1 functions to 
regulate some cellular and viral gene expression[160, 161]. 
EBNA-2 
EBNA-2 is a critical EBV transcription factor that modulates transcription of both 
cellular and viral genes [162, 163]. It does not, however, bind DNA directly, but instead 
associates with the cellular RBPJkappa and ZNF143 or the viral EBNA-LP [164-166]. 
EBNA-2 primarily associates with genes at the enhancer or intergenic regions to promote 
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expression [162, 166]. Importantly, EBNA-2 induces cell cycle entry and proliferation of 
cells by modulating cMyc and cMyc regulated genes and has been shown to be critical for B-
cell transformation [167-169]. EBNA-2 is expressed within 1 day of B-cell infection, in vitro, 
and during latency III and II, in vivo [19, 36, 170]. 
EBNA-3 family 
 The EBNA-3 family is made up of EBNA-3A, EBNA-3B, and EBNA-3C. They are 
all similarly regulated, expressed from the same viral promoter, and have similar gene 
structures. In vitro, the EBNA-3 family is expressed shortly after expression of EBNA-2 
[36]. Interestingly, EBNA-3A and EBNA-3C are critical for B-cell transformation, while 
EBNA-3B is dispensable [171, 172]. EBNA-3A and EBNA-3C have similar functions, but 
they cannot rescue deletions of the other for B-cell transformation [173, 174] All three family 
members have domains for binding RPBJkappa, have roles in repressing host transcription, 
and are coactivators for EBNA-2 [175]. EBNA-3A and EBNA-3C effect the expression of a 
number of cellular proteins [35]. Importantly, they have a role in downregulating cMyc 
transcription, by blocking EBNA-2 association with RPBJkappa, and repressing expression 
of the pro-apoptotic protein Bim, through promoter methylation [176-180].  EBNA-3C can 
also act as a coactivator for LMP-1 expression [172, 181]. EBNA-3B, conversely, is a tumor 
suppressor that upregulates CXCL10 for recruitment of EBV specific T-cells and has a 
growth inhibitory role [182]. 
BZLF1 
BZLF1 is the EBV lytic transactivator, which coordinates the switch from latent to 
lytic infection. Interestingly, it is expressed in the first few days of primary B-cell infection, 
and has been shown to be important, but not required for B-cell transformation, by helping to 
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induce cellular proliferation [183, 184]. BZLF1 is a cellular AP-1 transcription factor 
homolog [185]. It induces expression of EBV lytic early gene promoters by recruitment of 
the histone acetyl transferase, CREB [186, 187]. Interestingly, because EBV lytic genes are 
highly CpG methylated during latency, BZLF1 preferentially binds CpG methylated 
elements [188]. This allows for rapid and efficient reactivation. BZLF1 also functions to 
recruit viral replication machinery to the origin of replication by acting as an origin binding 
protein [189]. There are a number of different transcription factors that have been identified 
to induce and suppress BZLF1 expression, as its regulation critical to this transition into lytic 
replication or sustaining latency [190]. 
EBV antibody response 
The majority of infections with EBV go unnoticed and result in life long persistence 
of the virus. AIM, the disease that most commonly occurs following primary infection, has 
been previously diagnosed using heterophile antibody tests, however infections that occur 
asymptomatically at an early age of infection are less likely to generate a heterophile 
antibody response [191, 192]. Furthermore, these tests are non-specific and no longer 
recommended by the US Centers for Disease Control and Prevention. Anti-viral capsid 
antigen (VCA), anti-EBNA, and anti-early antigen diffuse (EA-D) antibodies have been 
studied extensively and are more reliably used clinically to identify both asymptomatic and 
symptomatic infection [193]. The classic antibody response against EBV is presented in 
figure 5. In general, VCA IgM is used to identify a recent infection, VCA-IgG for a past 
infection, and EBNA-IgG for distinguishing an acute from a convalescent infection [191]. 
Detection of antibodies against the EA-D during latent infection is indicative of reactivation 
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[194]. However, depending on the age, symptomology, and malaria exposure, some 
differences have been observed in the antibody response.  
Studies of asymptomatic infection have primarily focused on cross-sectional analysis. 
However, some early studies showed similar patterns of antibody response following 
asymptomatic infection of infants from both the United States and Gambia [195, 196]. This 
response was divided into four stages, depending on the detection of antibody. First, 
moderate titers of anti-VCA IgM and IgG were detectable. Second, VCA-IgG titers reached 
peak levels and VCA-IgM were at moderate levels. Interestingly, antibodies against the 
restricted component of the early antigen (EA-R) began to emerge. In contrast, once major 
difference between this response and AIM identified in these studies was that antibodies 
against the EA-D were detected following AIM, but not against EA-R [197]. The third stage 
consists of undetectable VCA-IgM, continued high titers of VCA-IgG, and peak titers against 
EA-R. Finally, in the fourth stage, VCA-IgG decline slightly and EA-R antibodies reach low 
levels. However, antibodies against EBNA-1 begin to become detectable. This delayed 
EBNA-1 response has been shown in both symptomatic and asymptomatic infection and is 
due to limited MHC class II processing and a delayed CD4+ response against this antigen 
[198].  
In a previous study from our group, understanding the role of malaria in EBV 
antibody response in children in Kenya, we also observed a waning of the VCA IgM in 
children from a malaria non-endemic region [199]. However, in a malaria endemic region, 
with more virus reactivation, anti-VCA IgM responses did not wane. This is consistent with 
an earlier study in these two populations, in which we showed higher level of sustained IgG 
antibody against VCA, EBNA-1, Zta, and EA-D in a malaria endemic region, compared to a 
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non-endemic region [200]. This suggests a difference in antibody response in infants from a 
malaria endemic region.  
Asymptomatic infection in adults has shown a similar pattern of antibody response as 
seen in children and following AIM. For instance, infection results in an early anti-VCA IgM 
response followed by high levels of VCA-IgG antibodies [201]. Again, IgG antibodies 
against EBNA-1 were more delayed. However, this study primarily focused on the T-cell 
response against EBV and the antibody data was used as a clinical indicator of infection. No 
difference was observed between the adult and child response asymptomatic infection 
analyzing these antigens. However, there is only a limited understanding of the antibody 
response following asymptomatic infection in adults.  
More thorough longitudinal studies can be performed following AIM, due to the 
ability to infer primary infection based on the symptoms observed, compared to the difficulty 
of understanding a response in a clinically silent infection. One group analyzed the kinetics 
against eight EBV antigens using an immunoprecipitation assay following AIM [202]. In the 
set of antigens that were analyzed, antibodies against the early lytic genes BMRF1 and 
BZLF1, and the late lytic protein BRLF2, were the earliest to generate peak IgG responses. 
This was followed by the peak responses against a second group, the early lytic protein 
BHRF1, the late lytic gene BFRF3, and the glycoprotein gp42. Finally, antibodies against 
EBNA-1 and gp350 were the last to reach peak levels. The time to peak levels also directly 
correlated with the level of the antibody, as the antibodies that reached the highest levels 
above background were the last to reach this level. Another study observed the presence of 
VCA-IgM and gp350-IgG antibodies prior to onset of AIM symptoms [203]. They also 
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observed a biphasic response for gp350 antibodies. Importantly, gp350 antibody levels were 
found to be inversely correlated with severity AIM symptoms.  
The gp350 antibody response is important to understand as it has been shown to be 
most correlated with EBV neutralization in a flow cytometry based assay [204]. More 
specifically, a recent study has shown that the gp350 specific IgG1 isotype of antibodies was 
most responsible for this in both a PCR based neutralization assay and an antibody mediated 
phagocytosis assay [205]. Therefore, the gp350 response is of much importance to the 
development of an EBV vaccine. However, this response has yet to be examined in 
asymptomatic infection.  
EBV is commonly transmitted through saliva or breast-milk, as we have shown in a 
Kenyan population, and enters the body through the oral cavity [15, 16]. In mucosal surfaces, 
such as this, IgA antibodies are more predominant [206]. This suggests that understanding 
the IgA response against EBV could be important for protection. However, the majority of 
studies have focused on the IgM and IgG response to EBV. One study, looking at the 
prevalence of these antibodies, could not detect gp350-IgA antibodies in people from Canada 
that were healthy carriers or with AIM [207]. However, levels of gp350-IgA antibodies are 
higher in the serum of people with NPC from Taiwan, a high-risk NPC region, compared to 
healthy controls from the same region [208]. The higher gp350-IgA antibodies were also 
observed in NPC patients from Malaysia and are viewed as a predictive for this cancer [209]. 
This higher level of IgA antibodies did not confer protection against NPC. Interestingly, 
gp350-IgA antibodies have been shown to enhance the infection of epithelial cells in vitro, 
while still blocking EBV infection of B-cells in a transformation assay [93]. This phenotype 
was observed through an epithelial cell specific polymeric immunoglobulin receptor. 
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Because of this, gp350-IgA antibodies have been suggested to have a pathogenic role in 
epithelial cell based diseases. The generation of gp350-IgA antibodies following primary 
EBV infection has not been explored. 
EBV vaccine development 
Viral glycoproteins have historically been the primary candidate antigens for vaccines 
designed to generate sterilizing immunity. As previously described, gp350 binding to CD21 
or CD35 is required for B-cell infection and neutralization is best correlated to the anti-gp350 
antibodies in plasma [204]. Therefore, animal studies and human clinical trials aimed at 
sterilizing immunity have primarily been focused on immunizations with the viral gp350. 
Immunizations with recombinant or purified gp350 protein have been shown to 
induce neutralizing antibodies in multiple animal models. This has been reported in mice, 
rabbits, cotton-top tamarins, and owl monkeys [210-215]. These studies have focused on in 
vitro neutralization of human cells as the primary read-out for neutralizing antibodies. 
Furthermore, in some studies where T-cell responses were characterized following 
immunizations, both EBV specific CD4+ and CD8+ T-cell responses have been reported 
[212, 216, 217]. gp350 vaccination has also shown some efficacy using EBV challenge 
primate models. 
Cottontop tamarins develop EBV positive B-cell lymphomas following infection with 
a high titer of virus [218]. As early as 1985, it was observed that tamarins immunized with 
gp350 containing cell membranes generated EBV neutralizing antibodies and were protected 
from tumors [219]. This has been shown in multiple studies containing different formulations 
of vaccines containing gp350 in tamarins [220]. Infection of common marmosets results in an 
AIM like diseases and immunization with a vaccinia or adenovirus expressing gp350 reduced 
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EBV replication after challenge [220, 221]. However, in some studies where a neutralizing 
antibody response was not detected, following immunization of tamarins, there was still 
protection from an EBV challenge. Furthermore, some studies have shown that neutralizing 
antibodies in serum are not always indicative of protection [222-224]. The majority of 
studies, however, show gp350 immunization resulting in some form of protection against 
either infection or disease. Therefore, there have been some human clinical trials to 
determine the efficacy of a vaccine containing gp350. 
In the first human EBV vaccine trial, a live recombinant vaccinia virus containing 
gp350 was administered to EBV seronegative infants [225]. This immunization was 
successful in generating neutralizing antibodies and only 3 of 9 infants were infected with 
EBV within 16 months, compared to infection of 100% of the infants that were not 
vaccinated.  However, this recombinant vaccinia virus vaccines have not been viewed as 
viable as general population vaccine platforms and other approaches have been attempted.  
A phase 1 trial was performed using a recombinant gp350 vaccine developed in 
Chinese hamster ovary cells [226]. Antibody against gp350 was detected in all seronegative 
subjects who received the vaccine. In this phase 1/2 trial, anti-gp350 antibodies were 
detected in all seronegative, vaccinated participants, but only 50-60% generating neutralizing 
antibodies. In a phase 2 trial, the vaccine was shown to reduce the incidence of infectious 
mononucleosis by 78%, but the incidence of asymptomatic infection was the same in the 
vaccinated group compared to those that were not vaccinated [227]. Therefore, sterilizing 
immunity was not generated by this vaccine. 
More recently, different formulations of multimeric gp350 have been used to improve 
the efficacy of this vaccination in mouse models. A tetrameric gp350 expressed by Chinese 
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hamster ovary cells produced 19-fold higher neutralizing antibodies in mice, compared to 
soluble gp350 [228]. In another study, the gp350 ectodomain fused to ferritin or encapsulin, 
bound to nanoparticles showed a 1000-fold increase in neutralizing antibody titers [229]. 
Finally, immunization of mice with a Newcastle disease virus based virus like particle 
expressing gp350 showed higher neutralizing antibody titers levels, though not statistically 
significant [230]. However, these formulations have yet to be tested in human clinical trials. 
gp350 has been the primary candidate of a vaccine with in vitro neutralizing titers as 
the primary readout. However, these vaccinations have not proved to be sterilizing in human 
trials. Groups have proposed targeting gp350 along with other EBV glycoproteins, like 
gHgL, but studies have not progressed as they have with gp350 [231]. Unfortunately, these 
studies have not taken into account the two types of EBV and their role in protection, as these 
trials have been done in only EBV-1 prevalent areas.  
Dissertation summary  
One major goal in the field of EBV is the development of an effective EBV vaccine 
that prevents infection. A sterilizing vaccine would dramatically reduce the incidence of 
EBV associated diseases. However, there are many challenges that are faced in the 
development of these vaccines. For example, a younger age of primary infection is a risk 
factor for the EBV associated cancer, Burkitt’s lymphoma. In Kenya, where Burkitt’s 
lymphoma is common, EBV infection occurs at a very young age and the neutralizing 
antibody response has yet to be explored thoroughly in infants of this age [232]. Furthermore, 
both types of EBV are common in these areas, another aspect of EBV that has not been 
explored in relation to vaccine development. More recently, we have described the infection 
of T-cells by EBV-2 in vitro and in vivo in a Kenyan infant population. Studies are ongoing, 
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but little is known about this infection. Particularly, as it relates to vaccines, it is of 
importance to determine the viral glycoprotein and receptor interactions that is important for 
this infection. This will allow us to target specific EBV antigens that would prevent this 
infection as well. In the work described here, we attempt to study some of these aspects of 
EBV infection and protection, with the goal of providing data to promote the development of 
an efficacious EBV vaccine.  
This dissertation focuses on EBV-2 infection of T-cells, primarily using an in vitro 
system to understand the role of entry glycoproteins and receptors for this infection and the 
early gene expression that occurs post infection. This work also focuses on the humoral 
immune response against EBV in an area of Kenya where co-infection with both EBV-1 and 
EBV-2 are common and the ability of plasma antibodies to neutralize infection of EBV-2 in 
vitro. In chapter 2, we show that EBV-2 infects T-cells through the EBV glycoprotein gp350 
and the cellular receptor CD21. In chapter 3, we describe the early kinetics of viral gene 
expression following of T-cell infection with EBV-2. We also describe differences between 
EBV-1 and EBV-2 early in B-cell infection. In chapter 4, we describe the kinetics of EBV-1 
and EBV-2 infection within a Kenyan infant cohort and propose the importance of the 
gp350-IgA antibody response in preventing co-infection with a different type of EBV. In 
chapter 5, we describe the ability for plasma to enhance the infection of T-cells in vitro. 
Finally, in chapter 6 we will discuss the major findings of this work and its importance in the 



























Figure 1. EBV in vivo life cycle as proposed by Thorley Lawson [19]. EBV is transmitted through saliva and breast milk. The virus 
initially infects and replicates in oral epithelial cell or directly infects naïve tonsillar B-cells. In this cell type, all latency genes are 
expressed. This drives the cells into a memory phenotype, progressively shutting down latent gene expression. The virus is 
maintained in memory B-cells for the life of the host, with EBNA-1 being expressed during proliferation.  Upon plasma cell 















































Figure 2. Antigen activated B-cell pathway. A naïve B-cell encounters its cognate antigen through the BCR, inducing activation 
signaling. CD4+ T-cells are stimulated through antigen peptide presented on MHC by antigen presenting cells. Activated B-cells and 
T-cells interact through MHC presentation of antigen peptide and CD40/CD40L. The B-cell then enters the dark zone of the 
germinal center where it undergoes SHM and proliferation. The B-cells are then selected with antigen presented by follicular 
dendritic cells and receive CD40 signals through follicular helper T-cells. This selection results in three fates; 1) apoptosis, 2) 
recirculation into the dark zone of the germinal center, 3) differentiation into a memory B-cell or a antibody secreting plasma cell.  
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Figure 3. EBV type distribution A) The global distribution of EBV infection with different 
EBV types from healthy people with no EBV associated diseases. B). The prevalence of 
EBV infection within healthy people, independent of geographic location, compared to HIV 
































































Figure 4. EBV entry mechanisms A) Entry mechanism required for EBV into B-cells. Initial attachment between the viral gp350 and 
cellular CD21 or CD35. This induces endocytosis of the virion. The second interaction occurs between gp42, in complex with gHgL, 
with HLA Class II molecules. This induces fusion between the viral envelope and endocytic membrane by gB, leading to uncoating 
and release of the viral capsid within the cell. B) Entry mechanism required for EBV into epithelial cells. gHgL initially interacts 
with either αvβ5, αvβ6, αvβ8, or ephrin receptor A2. This leads to gB, interacting with neuropilin-1, to promote fusion of the viral 
envelope with the cellular membrane directly at the cell surface. This allows for uncoating and release of the capsid into the 
cytoplasm.  
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Figure 5. Classic EBV antibody response. Following primary infection, VCA-IgM rises 
rapidly and then quickly wane. VCA-IgG, also rises rapidly, reaching higher titers than IgM 
and sustain much longer than IgM. EAD-IgG antibodies are then detectable, but rise and fall 
relatively quickly. The IgG response against EBNA-1 are delayed, but once generated are 
sustained. If the virus reactivates, the primary indicator is EAD-IgG antibodies, which rises 
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CHAPTER II 
EPSTEIN-BARR VIRUS TYPE 2 USES GP350 AND CD21 TO INFECT T-CELLS 
Abstract 
 Epstein-Barr virus (EBV) is associated with a number of diseases of infected T-cells, 
including some peripheral T-cell lymphomas, hemophagocytic lymhpohistiocytosis, and 
chronic active EBV. However, studies into these diseases have been limited due to the lack 
of an in vitro infection system of mature T-cells. We have recently described the ability for 
isolates of the less common strain of EBV, EBV type 2 (EBV-2) to infect T-cells [47]. 
Understanding the susceptibility of T-cells to EBV-2 infection is important to understanding 
the etiology of these diseases. Therefore, in this study we sought to determine the entry viral 
glycoproteins and cellular receptors that are involved in infection of T-cells.  Using an in 
vitro neutralization assay, we have determined that antibodies against the viral glycoprotein 
gp350 and the cellular CD21 block EBV-2 infection of both primary mature T-cells and the 
T-cell line Jurkat. The level of CD21 expression on different cell populations also directly 
correlates to the level of infection of those populations for both primary and Jurkat T-cells. 
We have identified type specific differences in the binding region of CD21, which may 
contribute to the unique ability of EBV-2 to infect T-cells. However, it is still unclear 
whether the CD21 receptor is unique on T-cells, compared to B-cells. The use of CD21 is 
encouraging for vaccine efforts that have been using this glycoprotein as a target antigen in 
their ability to prevent T-cell infection and EBV associated T-cell diseases.   
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Introduction 
Epstein-Barr virus (EBV) has been well described to infect B-cells and epithelial cells 
in vitro and in vivo. The virus was first discovered in Burkitt’s lymphoma derived B-cell 
lines and has been associated with other B-cell lymphoproliferative disorders since, including 
Hodgkin’s lymphoma, post-transplant lymphoproliferative disease, and AIDS associated B-
cell lymphomas [3-6]. EBV has also been found to be associated with epithelial cell cancers, 
including nasopharyngeal carcinoma and gastric carcinoma [7, 8]. Less well characterized is 
the role of EBV in diseases of infected T-cells. These include peripheral T-cell lymphomas, 
hemophagocytic lymphohistiocytosis, hydroa vacciniforme, and chronic active EBV [9, 12, 
13]. 
EBV has been classified into two major strains, EBV type 1 (EBV-1) and type 2 
(EBV-2) based on genetic differences in the Epstein-Barr nuclear antigen (EBNA) -2, 
EBNA-3a, and EBNA-3c latent genes [37-42]. These genetic differences, particularly in 
EBNA-2, cause a reduced ability for EBV-2 to immortalize B-cells in vitro, which EBV-1 
readily accomplishes [48, 49]. Geographically, EBV-2 is more limited, being mostly 
predominant in areas of Sub-Saharan Africa and Papua New Guinea. However, in EBV-2 
prevalent regions, the association with either type of EBV in Burkitt’s lymphoma has been 
found to be equivalent [73].  
Understanding T-cell susceptibility to EBV infection and the role of EBV in 
associated T-cell diseases has been limited due to the lack of in vitro infection of primary T-
cells and limited examples of infection of T-cells in healthy carriers, in vivo. Until recently, 
only the infection of immature thymocytes has been described in vitro [80]. This infection, 
however, was only shown with the EBV-1 strain B95.8 and proliferation induced by this 
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infection was not seen with the EBV-2 strain P3HR1 [81]. We have shown that strictly EBV-
2 strains, including the P3HR1 parent strain Jijoye, have the ability to latently infect primary 
mature T-cells in vitro [47, 233]. This infection is characterized by proliferation, activation, 
and expression of EBV latency genes. In addition, we have described EBV-2 infection of 
peripheral T-cells in healthy infant children in Kenya [46]. These studies suggest a role for 
the infection of T-cells in the biology of EBV-2, unique from EBV-1.  
Understanding the viral glycoprotein and cellular receptors responsible for infection 
are essential for development of an efficacious EBV vaccine for the prevention of EBV 
associated diseases. The mechanism that allows for virus attachment and entry into the more 
classically infected B-cells and epithelial cells have been well characterized. Initial 
attachment to B-cells occurs through the most abundant viral glycoprotein on the surface of 
the virion, gp350, and its receptors, either CD21 or CD35 on the cell surface [83-88]. This 
initial attachment event induces endocytosis of the virion [89]. The next step involves the 
viral gp42, in a trimeric complex with gH and gL, binding to HLA Class II [94-96]. This 
allows for fusion with the endocytic membrane by the EBV glycoprotein gB [91, 124]. In 
contrast, neither gp350 or gp42 are required for epithelial cell infection. The initial 
attachment to epithelial cells is with the dimeric complex of gH and gL, with gH binding to 
αvβ5, αvβ6, or αvβ8 integrin, or more recently described ephrin receptor A2 [115, 116, 118, 
119]. This induces fusion directly at the plasma membrane with gB, which has been shown to 
bind neuropilin-1 [125]. Previously immature thymocytes have been shown to be infected by 
EBV in a CD21, gp350 dependent manner [80]. However, this mechanism has not been 
characterized for mature T-cell infection.  
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 Because of the recent finding that EBV-2 has the unique ability to infect primary T-
cells, one major question is what viral glycoprotein and cellular receptor is required for this 
infection. Here we report the expression of CD21 on peripheral T-cells, at a much lower level 
that on B-cells. However, despite these low levels, EBV-2 utilizes CD21, through 
interactions with gp350, to facilitate infection of mature T-cells.  
Methods 
Blood processing and T-cell purification 
 After obtaining consent, peripheral blood was taken from healthy U.S. adults as per 
protocol approved by the Institutional Review Board of the University of Colorado, Anschutz 
Medical Campus and according to the Declaration of Helsinki. Ficoll-Paque (GE Healthcare, 
Little Chalfont, United Kingdom) was layered under peripheral blood to isolate peripheral 
blood mononuclear cells (PBMCs). T-cells or B-cells were isolated by negative enrichment 
using the human Pan T-cell Isolation Kit or the Pan B-cell Isolation Kit, respectively. 
(Miltenyi Biotec). Purity analysis was performed following cell isolation via flow cytometry 
for CD3 and CD19. Primary cell cultures were grown at 37°C and 5% CO2. 
Cell-lines and virus production 
 The EBV-2 positive Burkitt’s lymphoma cell line Jijoye and the EBV negative cell 
line BL41 were maintained in complete RPMI (RPMI, 10% fetal bovine serum, 1% penicillin 
streptomycin, and 1% L-Glutamine) at 37°C and 5% CO2. Jurkat cells were maintained in 
complete RPMI with 10mM HEPES.  Jijoye cells was used in this study for production of 
virus and virus produced from this cell line has been shown to infect T-cells in vitro [47]. 
EBV virus stocks were generated as described before [234]. In short, Jijoye cells were treated 
with sodium butyrate and tetradecanyl phorbol acetate (4mM and 25ng/ml respectively). Cell 
	   31	  
debris was removed by centrifugation at 4,000g for 10 minutes at 4°C and supernatant was 
passed over a 0.45µm filter. Viral particles were then pelleted by ultracentrifugation at 
16,000g for 90 minutes at 4°C. Virus pellets were resuspended in 1/200 of original volume in 
complete RPMI with 100µg/ml bacitracin. Virus was DNase treated and encapsulated 
genomes were quantitated by quantitative polymerase chain reaction (PCR) using primers 
and probes designed to amplify a 70-base pair region of the EBV BALF5 gene and β-actin 
gene as a control for DNA input, as previously described [232]. Primer pairs for all assays 
are described in Table 1. All infections were done with a multiplicity of infection (MOI) of 5 
DNase resistant EBV copies per cell. 
Neutralization assay 
 qPCR based neutralization assay was adapted from Weiss and colleagues for T-cell 
infection [205]. 5x10
6
 (MOI=5) copies of Jijoye virus were incubated with 10µg of 
monoclonal antibody against EBV glycoproteins for 2 hours at 37°C in a total of 100µl 
complete RPMI. Antibody clones against EBV glycoproteins were targeting gp350 (72A1), 
gp42 (F2.1), gHgL (E1D1), and gH (CL59) [114, 235-237]. These antibodies were received 
as a gift from Dr. Lindsey Hutt-Fletcher (Louisiana State University Health Sciences Center, 
Shreveport LA). The antibody/virus mixture was added to 1x10
6
 cells in a total of 200µl in a 
96 well plate and incubated for 2 hours at 37°C. In some experiments, 1x10
6
 purified T-cells 
were incubated with 20µg of blocking antibody clones against CD35 (J3D3) (Beckman-
Coulter) and CD21 (171, 1048) in 100µl complete RPMI for 2 hours at 37°C [238]. CD21 
antibodies were received as a gift from Dr. Michael Holers (University of Colorado Anschutz 
Medical Campus, Aurora CO). Then, virus with or without antibodies was added to the T-
cells for 2 hours at 37°C. Following infection, the T-cells were washed three times with 
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phosphate-buffered saline (PBS) to remove any free virus and plated in 1ml complete RPMI 
in a 24 well plate and incubated for three days at 37°C with 5% CO2. After three days, cells 
were washed again three times with PBS, pelleted, and frozen at -80°C. DNA was extracted 
from the cells using the Qiagen DNeasy kit according to the manufacturer’s protocol 
(Qiagen). EBV viral load was determined as previously described by qPCR for the BALF5 
gene and β-actin (Table 1) [232]. The viral load following infection with virus or cells 
incubated with each monoclonal antibody was normalized to the viral load following 
infection with no antibodies. Experimental conditions were performed in triplicate.  
gp350 amino acid variation analysis 
gp350 amino acid sequences were downloaded from Genbank using previously 
published, annotated amino acid sequences [43]. Sequences were uploaded into Molecular 
Evolutionary Genetics Analysis (MEGA) 7 and aligned using the MUSCLE alignment 
algorithm [239]. Phylogenetic trees were generated using the maximum likelihood method. 
Genetic differences between EBV-1 and EBV-2 were identified manually from aligned 
sequences.  
Flow cytometry and cell sorting 
 Cells were analyzed for CD21 expression by flow cytometry. First, the cells were 
washed in flow cytometry buffer (PBS, 0.5% bovine serum albumin, and 2mM EDTA). Cells 
were then Fc blocked for 20 minutes. After washing cells were stained for 20 minutes with 
fluorophore conjugated antibodies against CD3, CD19, CD4, CD8, and CD21 (clone Bly4 or 
HB5). All experiments were run on the BD-LSR Fortessa X-20 (BD Biosciences). Data 
analysis was done using FlowJo 10 (Tree Star).  
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 For sorting, negatively isolated T-cells were blocked with Fc Block for 20 minutes. 
Cells were then stained for 20 minutes with a CD21-PE antibody (clone HB5). Cells were 
sorted on the BD Aria Fusion sorter (BD Biosciences). Gates were determined based 
unstained control.   
Gene expression analysis 
 For RNA analysis, cells were washed and cell pellets were frozen at -80°C. RNA was 
isolated using the Qiagen RNeasy mini-kit, as per manufacturer’s protocol (Qiagen). RNA 
was reverse transcribed into cDNA using the High-Capacity cDNA Reverse Transcription 
kit, according to the manufacturer’s protocol (Applied Biosystems).  
CD21 mRNA quantitation was performed using primers previously described [240] 
(Table 1). CD21 expression was run using the iTaq Universal SYBR Green Supermix and 
analyzed on the IQ5 real-time PCR platform (Biorad). PCR protocol was performed as 
follows: 50°C for 2 minutes, 95°C for 10 minutes, and 40 cycles at 95°C for 15 seconds and 
60°C for 1 minute. CD21 expression was normalized to an internal control primer and probe 
set against β2 microglobulin, as previously described (Table 1) [241]. Delta delta Ct analysis 
was used to compare expression in B-cells and T-cells from the same donor. 
EBNA-1, EBNA-2, LMP-1, LMP-2, and BZLF1 viral gene expression was performed 
using specific primer and probes and normalized to β2 microglobulin expression, as 
previously described [241](Table 1). This PCR was performed using the ITaq Universal 
Probes Supermix and run on the IQ5 real-time PCR platform (Biorad). PCR protocol was as 
follows: 95°C for 10 minutes and 45 cycles of 95°C for 15 seconds and 60°C for 1 minute 
[241]. An EBV-2 lymphoblastoid cell line was used as a positive control 
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CD21 exon analysis 
CD21 mRNA exon analysis was performed using primers designed to span CD21 
introns (Table 1). Primer set names correspond to the exons analyzed, and set 10-12/13 has 
been previously reported [242]. Analysis was performed on purified peripheral T-cells the 
EBV negative Burkitt’s lymphoma cell-line BL41. PCR was performed using the RedTaq 
ReadyMix PCR Reaction Mix (Sigma). PCR reaction protocol was performed as follows: 30 
cycles of 94°C for 1 minute, 55°C for 2 minutes, and 72°C for 3 minutes.  Exon expression 
and product size was confirmed run on a 2% agarose gel with ethidium bromide.  
Jurkat clone infections 
Jurkat cells were single cell sorted and individual clones were grown in complete 
RPMI with 10mM HEPES at 37°C and 5% CO2. The level of CD21 was determined for each 
clone by flow cytometry. Two clones, one CD21 low and one CD21 high were identified by 
flow cytometry as described above after staining with anti-CD21 (HB5). Viral load was 
measured 24 hours post infection with an MOI of 5 of Jijoye virus using the BALF5 and β-
actin real-time PCR described before [232].  
Statistical analysis 
Statistical analysis was done using Prism version 6.0 (GraphPad). For neutralization assays, 
analysis was performed using a Mann-Whitney test comparing Jijoye alone and Jijioye with 
monoclonal antibodies. Comparison of CD21 expression on CD4+ and CD8+ T-cells, 
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Results 
anti-gp350 and anti-CD21 antibodies neutralize T-cell infection 
 In this study, our goal was to identify EBV glycoproteins and cellular receptors that 
mediate T-cell infection. To determine the reliance of EBV-2 infection of T-cells on EBV 
glycoproteins known to be involved in the infection of other cell types, we employed a qPCR 
based neutralization assay, adapted for purified T-cells [205].  EBV-2 virus was incubated 
with 10µg of monoclonal antibodies against gp350 (clone 72A1), gp42 (clone F2.1), gHgL 
(clone E1D1), and gH (clone CL59), which have previously been shown to block infection of 
B-cells (72A1 and F2.1) and epithelial cells (E1D1 and CL59) [114, 235-237]. Following a 
2-hour infection, the cells were washed and cultured for three days. Upon analyzing viral 
load 3-days post infection (dpi), we observed neutralization of T-cell infection with only the 
anti-gp350 antibody (Figure 1A). Suggesting that gp350 is utilized for EBV-2 infection of T-
cells.  
 gp350 has two known receptors, CD21 (complement receptor 2) and, more recently 
identified, CD35 (complement receptor 1) [84-88]. Therefore, we used a similar 3-day 
neutralization assay to determine the role of these receptors in T-cell infection. We incubated 
the purified T-cells with blocking antibodies against CD35 (clone J3D3) or CD21 (clone 171 
or 1048). We observed both antibodies against CD21, but not against CD35, neutralized 
EBV-2 infection of T-cells (Figure 1B). Data from these assays suggest that, like B-cells, 
gp350 interactions with CD21 are important for T-cell infection by EBV-2. We next wanted 
to identify any unique aspects of EBV-2 that may facilitate this infection.  
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gp350 genetic differences between EBV-1 and EBV-2 
  EBV-2, unlike EBV-1, has the unique ability to infect primary T-cells in vitro and in 
vivo [46, 47]. Now that we have shown that anti-gp350 antibodies block T-cell infection, we 
sought to understand if there are differences in gp350 between the two EBV strains. 
Therefore, we analyzed the gp350 (BLLF1) amino acid sequences from recently published 
whole genome sequences from isolates from healthy individuals, individuals with different 
EBV associated diseases, and EBV positive cell lines [43]. From this study, we analyzed the 
gp350 sequence of 83 EBV isolates, including 69 that were EBV-1, 12 that were EBV-2, and 
2 that were hypothesized to be recombinant strains containing an EBV-2 EBNA-3c, but an 
EBV-1 EBNA-2 gene [43]. Upon a maximum likelihood phylogenetic analysis, we observed 
a distinct segregation between the EBV-2 isolates and the EBV-1 isolates (Figure 2A). This 
distinction corresponded with the EBNA-3c sequence and not the EBNA-2 sequence, as the 
recombinant strains segregated with the EBV-2 isolates. It is hypothesized that this linkage is 
due to the genetic closeness of gp350 and EBNA3 in the EBV genome [44]. Upon analyzing 
the amino acid changes that were distinct between two common EBV isolates, the EBV-1 
strain Akata and the EBV-2 strain Jijoye, we observed 12 amino acid changes within the first 
504 N-terminal amino acids of the gp350 gene (Figure 2B). 3 of these changes fell within 
one of the known CD21 binding regions for gp350 [243]. Notably, the second binding 
region, also the epitope for the anti-gp350 neutralizing antibody 72A1, was not altered [244]. 
We hypothesized that these differences may allow for the infection of T-cells by EBV-2. We 
have also shown that antibodies against the CD21, the gp350 receptor, also block infection of 
T-cells. However, the expression of CD21 on mature T-cells is controversial.    
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CD8+ T-cells express more CD21 than CD4+ T-cells 
 CD21 expression has been described on immature thymocytes and mediates EBV 
infection of these cells with EBV-1 [80]. Utilizing an anti-CD21 antibody, clone Bly4, we 
observed expression of CD21 on peripheral CD19+ B-cells, but could not detect expression 
of CD21 on peripheral T-cells (Figure 3A). However, antibodies against CD21 block 
infection of T-cells with EBV-2, suggesting that it is expressed. Interestingly, a number of 
studies have described the expression of CD21 on mature, peripheral T-cells and some T-cell 
lines [245]. These studies consistently used the anti-CD21 monoclonal antibody clone, HB5 
[246, 247]. Using this antibody by flow cytometry, we were able to detect expression of 
CD21 on peripheral CD3+ T-cells, as well as CD19+ B-cells (Figure 3B). Expression is 
much lower on T-cells, compared to B-cells. Utilizing the anti-CD21 (HB5) antibody, we 
observed expression of CD21 on both CD4+ and CD8+ T-cells (Figure 3C). Expression on 
CD8+ T-cells was higher than on CD4+ T-cells, in both percentage (p=0.0138) and 
geometric mean fluorescent intensity (gMFI) (p=0.0061) (Figure 3D and 3E). This is 
consistent with a higher level of infection in the CD8+ T-cell subset, compared to CD4+ 
[47]. However, due to this variable antibody detection, we wanted to understand any 
differences between B-cell and T-cell CD21.  
T-cells express lower levels of CD21 mRNA, but the transcripts contain the same exons 
To confirm the lower levels of CD21 expression seen by flow cytometry, we used 
real-time PCR to test for CD21 mRNA expression. To do this, we isolated B-cells and T-
cells from 3 donors and the expression of CD21 mRNA was analyzed for each cell subset. 
Using delta delta Ct analysis, we observed a 24.83, 6.79, and 5.32-fold higher levels of CD21 
mRNA from B-cells compared to T-cells, for each donor individually (Figure 4A). 
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Therefore, the mRNA expression corresponds to the lower levels of CD21 observed by flow 
cytometry.  
It is of great interest why EBV-2, but not EBV-1, has the ability to infect T-cells, 
while using the same receptor EBV-1 is known to bind on B-cells. The differences we have 
observed in gp350 could be used exploit cell type differences in CD21. Therefore, we wanted 
to determine if there was any alternative splicing occurring within the T-cells that could 
potentially change the structure of CD21 on T-cells. This difference was also hypothesized 
due to the difference in detection using the Bly4 anti-CD21 antibody (Figure 3A).  The CD21 
protein is made up of an extracellular domain composed of 16, 60-70 amino acid long, short 
consensus/complement repeat (SCR) domains, a single transmembrane domain, and a short 
intracellular domain [248]. The CD21 mRNA is composed of 21 spliced exons [249]. 
Primers were deigned to encompass the 16 exons that make up the extracellular portion of 
the CD21 transcript (Table 1). Furthermore, these primer sets spanned the spliced-out introns 
in order to distinguish genomic DNA from mRNA. We analyzed primary T-cells and 
compared that to the exon expression from the EBV negative Burkitt’s lymphoma cell-line, 
BL41. There was no observable difference in the expression of any of the CD21 exons 
between these two cell types (Figure 4B). Therefore, we concluded there is no difference in 
the splicing of the CD21 transcript between B-cells and T-cells.  
Low level CD21 expression can facilitate EBV-2 infection of T-cells 
 To further show the importance of CD21 on infection of mature T-cells, we sorted 
CD21 low and high T-cells in one experiment. To do this, CD3+ T-cells were negatively 
selected, confirmed for high purity, and sorted based on CD21 expression (Figure 5A and 
5B). Following cell sorting, the CD21 low population showed no detectable expression of 
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CD21 and the CD21 high population were 97.9% CD21 positive, by flow cytometry (Figure 
5C).  However, by real-time PCR, there was still detectable expression of CD21 mRNA in 
the CD21 low population (Figure 5D). The expression of CD21 in the CD21 high population 
was 21-fold higher than in the CD21 low population. Following infection, we still detected 
EBV-2 viral load 1 and 3-dpi in both the CD21 low and high populations (Figure 5E). 
Importantly, the infection level was lower in the CD21 low population than the high 
population, correlating to CD21 expression. In order to facilitate further experimentation, we 
wanted to determine the infection and role of CD21 in the Jurkat T-cell line.   
Jurkat T-cells are infected by EBV-2 through gp350 and CD21 
 A previous report has shown the presence of CD21 on the Jurkat T-cell line and 
variable infection ability with EBV-1 (B95.8) [247, 250]. In order to perform more analysis 
on CD21 on T-cells, we confirmed the Jurkat T-cell line for CD21 expression using the HB5 
antibody. We were able to detect CD21 expression by flow cytometry (Figure 6A). Similar to 
what is observed with primary cells, this expression was much lower than that of the B-cell 
line, Raji. Upon infection with EBV-2, we were able to detect an EBV viral load 24-hpi 
(Figure 6B). We were also able to detect the expression of EBV gene transcripts at this time-
point (Figure 6C). We detected expression of EBNA-2 and latent membrane protein (LMP)-1 
in all infection replicates. We only detected expression of the viral LMP-2 in one replicate.  
However, we did not detect transcription of the lytic gene, BZLF1 or the viral EBNA-1. This 
suggests that this infection induced the expression of viral genes and viral load was not 
simply to virus binding on the cell surface. Using a similar neutralization assay described 
earlier, we were able to show a reduction in viral load with virus incubated with the anti-
gp350 neutralizing antibody and with cells incubated with a CD21 blocking antibodies 
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(Figure 6D). This suggests, like primary T-cells, infection with the Jurkat T-cell line was 
mediated by the viral gp350 and its cellular receptor CD21.  
We single cell sorted Jurkat clones and identified two based on differences in CD21 
expression (Figure 6E). These clones were identified as CD21 low or CD21 high. Upon 
infection of the two clones with Jijoye virus, we observed a significantly higher viral load in 
the CD21 high clone compared to the CD21 low clone at 1-dpi (p=0.0009) (Figure 6F). Since 
CD21 expression on T-cells correlates to the level of infection, this further suggests that 
CD21 is important for infection of the Jurkat T-cell line.  
Discussion 
In this study, we show the use of the viral gp350, through interactions with the 
cellular CD21 for infection of primary T-cells and the Jurkat T-cell line with EBV-2, as 
antibodies against the viral gp350 and the cellular CD21 block infection of both. We 
hypothesize this infection is mediated by genetic differences between EBV-1 and EBV-2 in 
the viral glycoprotein gp350 within the previously described CD21 binding region [243]. 
Often overlooked, CD21 is expressed on peripheral T-cells and expression is higher on CD8+ 
T-cells compared to CD4+ T-cells, consistent to our previous study showing predominant 
infection of CD8+ T-cells [47]. These results provide a possible mechanism EBV uses to 
infect T-cells.  
One major question that remains is why EBV-2 infects T-cells, but EBV-1 cannot. 
Importantly, we have shown that EBV-2 binds SCR 1-2 of CD21, like it does on B-cells, as 
anti-CD21 antibody clones that are epitope mapped to those SCRs, 171 and 1048, block 
infection of T-cells [238]. We hypothesize that differences in the gp350 protein, specifically 
in the CD21 binding region, may create a higher affinity or avidity interaction between 
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gp350 and CD21, allowing the lower level of CD21 expression on T-cells to be sufficient for 
infection. Interestingly, EBV associated T-cell cancers are predominant in Asia, an EBV-1 
predominant region [251]. Furthermore, these cancers can be infected with EBV-1 (H. 
Kimura, personal communications). Unfortunately, there is no EBV sequence data available 
from T-cell diseases that describe the gp350 gene. This information would be important to 
understand if the isolates that cause these diseases have unique gp350 sequences allowing for 
infection.  
It could also be hypothesized that differences in the CD21 expressed on T-cells, in 
combination with gp350 differences, allow EBV-2 infection. These differences could be in 
the level of expression, the structure of this receptor, or in the complex CD21 is in on T-cells. 
A previous study has compared the expression of CD21 in primary B-cells and T-cells, 
showed similar mRNA expression, but no detectable CD21 surface expression on T-cells 
[252]. However, we have shown that expression of CD21 is much lower than what is 
expressed on B-cells by flow cytometry and mRNA expression. Interestingly, even T-cells 
that have CD21 levels below the level of detection by flow cytometry still expressed CD21 
mRNA and facilitated infection with EBV-2, though viral load was lower. Like gp350 
differences, analysis of CD21 on T-cells has not been performed on samples from a high-risk 
population or people with EBV associated T-cell diseases. This could provide insight into the 
susceptibility of T-cell infection.  
CD21 on T-cells is also thought to be structurally different than that on B-cells [245]. 
For instance, two antibody clones used in this study were able to detect expression of CD21 
on B-cells, but only one, clone HB5, was able to detect expression on T-cells. The HB5 
antibody has been mapped to SCR 3-4, but the Bly4 antibody has yet to be epitope mapped 
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[253]. Importantly, we have not observed any difference in the splicing of the CD21 mRNA 
transcript, at an exon expression level, between peripheral T-cells and the BL41 B-cell line. 
A previous study has shown by western blot that the molecular weight of CD21 on T-cells 
and B-cells was equivalent [247]. One cell type specific difference between CD21 is that this 
receptor is likely in a unique complex on T-cells. 
Classically, CD21 is complexed with CD19, CD81, and Leu-13 or with CD35 on B-
cells [254, 255]. However, CD19 is a B-cell specific protein, suggesting that this complex is 
different on T-cells. One study that has explored this complex identified CD21 as a stand-
alone molecule on some T-cell lines [256]. However, upon ligation with monoclonal 
antibodies or C3d, the CD21 ligand, two proteins of 105 and 55 kD were recruited into a 
complex with CD21. These proteins have yet to be defined or experimentally observed on 
primary T-cells.  It would be important to understand the proteins CD21 is in complex with 
on T-cells and the interactions and signaling that occur downstream of gp350 ligation. This 
would give us insight into the currently unknown function of CD21 on T-cells. It has been 
hypothesized to be involved in cytotoxic T-cell adherence to C3 complement bound targets 
[247]. However, few studies have attempted to determine the function of CD21 on T-cells. It 
would be important to understand its role in T-cell biology.  
We hypothesize that the expression of CD21 in Jurkat T-cells is important for 
survival. In an attempt to show the reliance of CD21 expression for EBV-2 infection, we 
employed two methodologies to knock-out CD21expression. We first used clustered 
regularly interspaced short palindromic repeats (CRISPR) and CRISPR associated protein 9 
(CAS9) technology with two unique guide RNAs specific against CD21. After single cell 
sorting 376 clones that were successfully transfected with the CRISPR/CAS9 and guide RNA 
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plasmid, no CD21 knock-out clones successfully expanded. As an alternative method to 
knock-out CD21, we transduced Jurkat cells with a lentiviral vector containing a plasmid that 
expressed CD21 specific short hairpin RNAs and conferred puromycin resistance. However, 
upon selection, no puromycin resistant cells grew out from the CD21 shRNA transduced 
cells. Interestingly, the transduction and puromycin selection was successful with a lentiviral 
vector containing a scrambled shRNA control plasmid. Suggesting, the transduction and 
selection methods were successful for Jurkat cells. However, again CD21 knock-out cells did 
not survive. This indicates to us an important function for CD21 on the Jurkat T-cell line. 
However, this should be explored further and these strategies should be attempted using other 
T-cell lines.  
It is unlikely that CD21/gp350 is the only interaction that mediates infection of T-
cells. All herpesviruses require the engagement of the core fusion machinery for infection, 
this includes the glycoproteins gH, gL, and gB [106]. These proteins are involved for EBV 
infection of both B-cells and epithelial cells [91, 97, 112-114]. It is likely that these proteins 
play some role, whether directly binding a receptor on the cell surface or conformational 
changes that are involved in fusion. Additional interactions between EBV-2 and T-cells 
should be explored.  
An efficacious, sterilizing EBV vaccine has yet to be developed. The primary target 
of vaccine candidate has been the viral glycoprotein gp350. Because gp350 is one 
glycoprotein involved in T-cell infection, it is likely that gp350 remains a viable vaccine 
candidate. However, with the generation of more sequence data, it has become apparent that 
gp350 is a highly variable protein, even within EBV-1 strains. Importantly, as we have 
shown here, there are major differences between EBV-1 and EBV-2 in the gp350 protein, 
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specifically in epitopes that would be important for neutralization. It would be wise to 
consider this genetic variability in both EBV-1 and EBV-2 for the formulation and design of 
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Table 1. Primer and probe sets used for this study identified by the viral or cellular target for 
real-time PCR.  For the CD21 exon analysis, primer pairs are identified by the exon number 
that the primer set spans.  
 
Real-time PCR 
PCR Target Forward Primer 5'- 3' Reverse Primer 5'-3' Probe 5'-3' 













GAGTATGCCTGCCGTGTG AATCCAAATGCGGCATCT CCTCCATGATGCTGCTTACATGTCTC 
CD21 Exon Analysis 
1 - 2 GGGGTTTTCTTGGCTCTCGT GTACCAACAGCAATGGGGGT  
3 - 5 TGTGAAGAGGCACGCTGTAA GCAACTCCCTGTCCAGCAAT  
5 - 6 GCTTGGACCAAAATGCCAGT GGACACTGAACCGCAGAAGT  
6 - 7 CTTCTGCGGTTCAGTGTCCA CACACCCCCTCAGAGGTACA  
7 - 8 AGTGTACCTCTGAGGGGGTG TCCTGTAGCTTCACACGCTG  
8 - 9 CAGCGTGTGAAGCTACAGGA GGAATTGTGCCTTGACACTCC  
9 - 10 ATCAGGAGTGTCAAGGCACA ATGTGAGCACTGGACAGCAA  
10 - 12/13 AGAGCACCATCCGTTGTACA CCAGTCAACTGGTACCCATC  
14 - 15 CTTCCCCACAGTGCTTACGA TCCACCAGTATGGTTCCCGT  
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Figure 1. A) Neutralization assay after incubating virus with monoclonal antibodies against 
EBV glycoproteins. Mock (uninfected cells), Jijoye (no antibody), anti-gp350 (clone 72A1) 
(p=0.0022), anti-gp42 (clone F2.1) (p=0.6991), anti-gHgL (clone E1D1) (p=0.4610), and 
anti-gH (clone CL59) (p=0.3939). Viral loads were normalized to the uninhibited Jijoye 
infection for each experiment and presented as normalized infection [(Jijoye + antibody EBV 
copies/µg β-actin DNA)/(Jijoye only EBV copies/µg β-actin DNA)]. n=3 donors B) 
Neutralization assay with incubation of purified T-cells with monoclonal antibodies against 
CD35 (Clone: J3D3) (p=0.1174) or CD21 (clone: 171 and 1048) (p=0.0061 and p=0.0061). 
Viral loads were normalized to infection with uninhibited Jijoye infection [(Jijoye + antibody 















































































































Figure 2: A) Phylogenetic analysis of gp350 amino acid sequences were performed using 
MEGA software and maximum likelihood phylogenetic tree is presented. Isolates are 
identified with the GenBank accession number.  Clinical isolates are identified with the 
abbreviated disease or cell type and location of origin and common cell lines are labeled with 
the cell line name. (Post-transplant lymphoproliferative disease – PTLD, Hodgkin’s 
lymphoma – HL, Burkitt’s lymphoma – BL, infectious mononucleosis – IM, nasopharyngeal 
carcinoma – NPC, gastric carcinoma – GC, lymphoblastoid cell line - LCL) The EBNA-2 
and EBNA-3c type associated with each isolate are also presented. (White – EBV-1, Gray – 
EBV-2) B) Amino acid sequence (A.A.1-504) of the gp350 protein for the EBV-1 strain 
Akata. The known CD21 binding regions are underlined. The Amino acid changes for the 
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Figure 3. Representative flow cytometry plot of PBMCs labeled with CD19, CD3, and CD21 
A) clone Bly4 and B) clone HB5. CD21 expression on CD19+ B-cells (left) and CD3+ T-
cells (right). Gates were set based on unstained control. C) Representative gating strategy for 
CD21 analysis of total CD3+, CD8+ and CD4+ T-cells. D) Comparison of the % CD21 
positive cells in the total CD3+, CD4+, and CD8+ T-cell populations (p=0.0138). n=5 E) 
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Figure 4. A) CD21 gene expression analysis of T-cells and B-cells from the same donor. 
Graph represents the fold change expression difference of B-cells over T-cells based on ΔΔCt 
analysis. Fold Change = 2^-([B-cell CD21 Ct – B-cell β2 microglobulin Ct] – [T-cell CD21 
Ct – T-cell β2 microglobulin Ct]) B) PCR gel analysis of CD21 exons comparing the B-cell 
line, BL41, and purified peripheral T-cells. Primer sets are labeled by the exon they are 
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Figure 5. A) T-cell purity analysis of T-cells for CD21 sorting, (Red – Unstained, Blue – 
CD3-stained). B). Sorting gates used for CD21 T-cell sorting. Unstained control (left) and 
sort gating strategy (right). C) Post-sort analysis of cell populations analyzing CD21 
expression. D) CD21 gene expression analysis post infection (ΔCt = CD21 Ct – β2 
microglobulin Ct). Mock (uninfected cells), 24-hpi, and 72-hpi analysis for CD21 low and 
CD21 high sorted populations. E) EBV viral load in 24 and 72-hpi of sorted CD21 low and 
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Figure 6. A) CD21 (clone HB5) expression on unstained Jurkat (light gray), unstained Raji 
(dark gray), Jurkat (green) and Raji (blue). B) Viral load 24-hpi following infection of Jurkat 
cells with Jijoye virus. Uninfected cells (mock) are a negative control. Data is represented as 
log (EBV copies/1x10
6
 cells). n=4 C) ΔCt analysis of viral gene expression of LMP-1, LMP-
2, EBNA-1, EBNA-2, and BZLF1 expression normalizing expression to cellular β2 
microglobulin expression (ΔCt =EBV gene Ct – β2 microglobulin Ct). Uninfected cells 
(mock) are a negative control. n=4 D) Neutralization assay using Jurkat cells and infecting 
with Jijoye virus. Viral loads were normalized to the uninhibited Jijoye infection of Jurkat 
cells, [(Jijoye + antibody EBV copies/µg β-actin DNA)/(Jijoye only EBV copies/µg β-actin 
DNA)]. Virus was either incubated with the anti-gp350 antibody (clone: 72A1) (p=0.0022) or 
the cells were incubated with an anti-CD21 antibody (clone: 171) (p=0.0411). n=6 E) CD21 
expression of Jurkat clones, CD21 low (Red) and CD21 High (Purple), unstained control 
(gray). F) Viral load 24-hpi of the CD21 low and high Jurkat clones. Uninfected cells (Mock) 
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CHAPTER III 
 EARLY EVENTS IN EBV INFECTION 
Abstract 
 In vitro infection and transformation of B-cells with Epstein-Barr virus (EBV) has 
been used as a model of latency and persistence for the virus. We have recently described the 
ability for EBV to infect T-cells in vitro with isolates from a less common strain of EBV, 
EBV type 2 [47]. In that report, we have previously described a pattern of viral protein 
expression, unique from what has been observed following B-cell infection, in vitro. 
However, the pattern of viral gene expression in B-cell infection has only been described 
using isolates from the more common EBV strain, EBV type 1 (EBV-1). In this study, we 
have shown that there is expression of EBV latency genes, but no lytic gene expression, 
within 24 hours of infection of T-cells with EBV-2. This includes the detection of translation 
competent, virion associated RNAs that are transferred during infection. Upon infection of B-
cells, we observe the same latent RNAs transferred by EBV-2, but only a low level of latent 
transcripts transferred by EBV-1. The most abundant transcript transferred by EBV-1 is the 
lytic transactivator, BZLF1, much higher than what is transferred in EBV-2 infection of B-
cells. Consistent with this, previous studies have reported an early prelatent phase of 
infection in which lytic genes are expressed, inducing B-cell proliferation and preventing cell 
death. One major difference between EBV-1 and EBV-2 is a diminished ability for EBV-2 
strains to transform B-cells, in vitro. Therefore, we hypothesize this difference in the transfer 
of virion associated RNAs, specifically BZLF1, is in part responsible for the impaired ability 
for EBV-2 to transform B-cells in vitro.  
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Introduction 
Epstein-Barr virus (EBV) is a near ubiquitous human gammaherpesvirus, with greater 
than 95% of the world’s population infected [1]. In vivo, EBV is transmitted into the oral 
pharynx through saliva, initially infecting the oral epithelial cells or the tonsillar B-cells [15-
18]. Primary infections are most commonly asymptomatic, especially if one is infected early 
in life. If infected later in adolescence, patients can develop, the most common EBV 
associated disease, infectious mononucleosis [2]. Following primary infection, the virus goes 
latent within the host’s B-cell compartment and persists within memory B-cells, with 
sporadic reactivation events occurring throughout life [19]. In some cases, infection can drive 
the development of lymphoproliferative diseases and cancers, including Burkitt’s lymphoma, 
nasopharyngeal carcinoma, chronic active EBV, and peripheral T-cell lymphomas [3, 7, 9-
11]. Importantly, much of what we know about latency establishment has come from in vitro 
studies following EBV immortalization of B-cells into lymphoblastoid cell-lines (LCLs).    
In vitro, there is a distinct pattern of gene expression following B-cell infection with 
EBV, ultimately resulting in an immortalized cell-line with a latency III viral gene expression 
pattern, in which all EBV latency genes are expressed [36]. Approximately 1-5% of the cells 
in an LCL are undergoing lytic gene expression, depending on the cell line [36]. Within the 
first day of infection, there is abundant lytic gene expression, including the viral lytic 
transactivator BZLF1, known as the prelatent phase [183, 257, 258]. BZLF1 is an important 
viral transcription factor that can interact with a number of cellular proteins and drive 
quiescent B-cells into cell cycle, while also inducing expression of a number of lytic viral 
genes [183, 190]. Within 24-hours of infection, there is also expression of the viral latent 
gene Epstein-Barr nuclear antigen (EBNA)-2 [36]. EBNA-2 is another important viral 
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transcription factor that is critical for transformation and drives expression of many host and 
viral genes, including c-Myc and LMP-1 [167-169]. This is followed closely by expression 
of EBNA-1 and EBNA-3a-c [36]. EBNA-1 induces some viral and cellular gene expression 
and tethering the viral genome to the cellular genome for latent replication [153-156, 160, 
161]. The EBNA-3a-c genes repress many host and viral genes that would be detrimental for 
LCL establishment, including the pro-apoptotic protein BIM [35]. At 7-days post infection 
(dpi), latent membrane protein (LMP)-1 and LMP-2 are detected, reaching peak levels 
around 14-dpi (Price, 2012). LMP-1, a CD40 mimic, is a constitutively active signaling 
molecule to promote survival and growth of expressing cells and is required for 
transformation [31, 32, 136, 139]. LMP-2, a host constitutively active BCR mimic, provides 
growth signals to the cell, but is not absolutely required for transformation [142, 149-151]. 
The latency III expression pattern, in which all viral latent genes are expressed, sustains 
through LCL immortalization and in long term LCL cultures [36].  
Virion associated RNAs have been described following in vitro infection with a 
number of herpesviruses, including herpes simplex virus 1 and cytomegalovirus, and the 
closely EBV related gammaherpesviruses, murine gammaherpesvirus 68 and Kaposi’s 
sarcoma associated herpesvirus [259-262]. A single study has described these early 
transcripts following EBV infection with the prototypical strain, B95.8 [263]. They observed 
the presence of many RNase resistant viral transcripts, both latent and lytic, within the 
encapsulated virion and 2-hours post infection (hpi) of B-cells. Furthermore, the transcripts 
were detected in the cell after treatment with the RNA polymerase inhibitor Actinomycin D, 
suggesting they were not de novo transcribed following infection. One of the virion 
associated transcripts, BNLF2a, is involved in immune evasion by inhibiting loading of 
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antigen on HLA Class I molecules [264]. In this study, a reduced CD8+ T-cell response was 
observed in wild-type viruses compared to BNLF2a knock-out viruses [263]. This phenotype 
persisted in the presence of actinomycin D treatment, suggesting a functional role for virion 
associated transcripts.  
Experimentally, the in vitro pattern of viral gene expression and virion associated 
RNAs have been studied using strains of the more common type of EBV, EBV type 1 (EBV-
1), which includes the strain B95.8.  However, there are major differences in some EBV 
latency genes, EBNA-2, EBNA3a, and EBNA3c, between EBV-1 and the less common EBV 
type 2 (EBV-2) [37-42]. More recently, a sequencing analysis of EBV isolates showed that 
all EBV-2 isolates analyzed had the V3 variant of Zp, the BZLF1 promoter [44]. This variant 
induces a greater amount of BZLF1 RNA [45]. Some of the differences, particularly in 
EBNA-2, have been associated with the reduced ability for EBV-2 to immortalize B-cells 
and differences in the host and viral gene expression following B-cell infection between the 
two types [48, 49, 265]. We have also shown, in addition to B-cells, EBV-2 has the unique 
ability to infect primary T-cells [47]. Infection of this cell type results in the expression of 
EBNA-1, EBNA-2, LMP-1, and LMP-2 protein as early as 1-day post infection. This pattern 
persists out to 12-dpi. We have yet to report on the viral mRNA expression of these genes or 
the expression of the lytic BZLF1.  
In this study, we had two main goals. The first was to describe the kinetics of viral 
gene expression that occur within 24 hours of T-cell infection by EBV-2, including any 
virion associated transcripts detected. This would allow us to determine if there was any 
early lytic gene expression or sequential pattern to latent gene expression following T-cell 
infection. Furthermore, we sought to determine if there were any differences in the virion 
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associated RNAs that were detected following B-cell infection with EBV-1 and EBV-2. This 
work could lead to an understanding of the effect of genetic differences between the two 
virus types and their role in RNA packaging within the virion.  
Methods 
Cell isolation 
 After obtaining consent, peripheral blood was taken from US adults, according to the 
protocol approved by the Institutional Review Board of the University of Colorado, Anschutz 
Medical Campus and the Declaration of Helsinki. Ficoll-paque (GE healthcare) was layered 
under the peripheral blood to isolate peripheral blood mononuclear cells (PBMCs). T-cells 
and B-cells were isolated separately from PBMCs through negative selection using the Pan 
T-cell Isolation Kit and Pan B-cell Isolation Kit, respectively (Miltenyi Biotec). Cells were 
analyzed for purity by flow cytometry using an CD3 and CD19 conjugated antibodies, for T-
cell and B-cell analysis, respectively. All cells were grown in complete RPMI (RPMI with 
10% fetal bovine serum, 1% Penicillin Streptomycin, and 1% L-Glutamine) at 37°C with 5% 
CO2. 
Virus production 
 The EBV-2 infected cell line Jijoye and the EBV-1 infected cell line B95.8 were used 
for virus production.  EBV infected cell lines were grown in complete RPMI at 37°C with 
5% CO2. Virus stocks were generated as previously described [234]. In short, cells were 
treated with 4mM sodium butyrate and 25ng/ml tetradecanyl phorbol acetate to induce lytic 
reactivation. 5-days post induction, cell debris was removed via centrifugation at 4,000g for 
10 minutes at 4°C. Supernatant was then filtered through a 0.45µm filter. Virus was pelleted 
via ultracentrifugation at 16,000g for 90min at 4°C and resuspended in 1/200 of the original 
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volume in complete RPMI with 100µg/ml bacitracin. Following DNase treatment, virus 
stocks were quantitated by qPCR using primers and probes specific to a 70bp region of the 




 cells were plated in 1ml of complete RPMI in a 24-well tissue culture plate. In 
some experiments, the cells were treated with 5µg/ml Actinomycin D or 25µg/ml 
cycloheximide 15 minutes prior to infection. Cells were infected with a multiplicity of 
infection (MOI) of 10, or 1x10
7
 virus copies per well. Cultures were maintained at 37°C with 
5% CO2. Cells were then harvested at indicated time points.  
RNA isolation and reverse transcription real-time PCR 
 At harvest, cells isolated for RNA were centrifuged at 600g for 15 minutes, washed 
with PBS, centrifuged again, and cell pellets were frozen at -80°C. RNA was isolated from 
frozen pellets via TRIzol Reagent extraction, as per protocol (Invitrogen). RNA was reverse 
transcribed into cDNA using the High-Capacity cDNA Reverse Transcription Kit, as per 
manufacturer’s protocol (Applied Biosystems).  Real-time PCR was performed on cDNA for 
expression of EBNA-1, EBNA-2, LMP-1, LMP-2, and BZLF1 using primers and probes 
previously described [241]. All reactions were run in biplex with primers and probes specific 
for a viral gene transcript and β2 microglobulin as an internal control. PCR conditions were 
as follows; 95°C for 10 minutes, 45 cycles of 95°C for 15 seconds and 60°C for 1 minute. An 
EBV-2 positive LCL was used for a positive control for latent genes and reactivated Jijoye 
cells were used for a positive control for BZLF1.  
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LMP-1 western blot 
 At the indicated time points, cells isolated for protein analysis were centrifuged at 
600g for 15 minutes, washed with PBS, and centrifuged again. Cell lysates were made using 
a 1:1 ratio of PBS and Laemmli buffer with 2-mercaptoethanol. Mixtures were then heated in 
boiling water for 5 minutes. 50µg of total protein was separated by SDS-PAGE with 10% 
acrylamide gels, followed by immunoblotting. Membranes were blocked in a 10% milk tris-
buffered saline (TBS) Tween-20 solution. Blots were then incubated overnight with a 
primary anti-LMP1 (clone SC1-4) antibody or anti-β-actin (clone mAbcam8224). The blots 
were incubated with a secondary goat anti-mouse horseradish peroxidase conjugated 
antibody. Protein was detected using ECL chemiluminescence substrate (GE Healthcare).  
Results 
24-hour kinetics of viral gene expression 
 We have established that EBV-2 infection of T-cells causes a latency III pattern of 
viral protein expression as early as 1-day post infection [47]. This is markedly different than 
what is observed following B-cell infection, in which latency III is not observed until 
approximately 7 to 14-dpi [36, 141].  There is also expression of BZLF1 during the prelatent 
phase in B-cells, along with other lytic genes, within 1 day of infection [183, 257, 258]. 
Therefore, we sought to understand if there is any stepwise progression of viral gene 
expression within 24-hours of infection that leads to the latency III expression pattern in T-
cells. We infected purified T-cells with EBV-2 virus and harvested from 0 to 24-hpi, 
sampling at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 16, 18, 20, and 24-hpi. Interestingly, we observed high 
and consistently detectable expression of LMP-1 and EBNA-2 latent gene transcripts (Figure 
1). We also detected low levels of transcripts for LMP-2 and EBNA-1. There was also no 
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detection of the lytic transcript BZLF1. Surprisingly, there was detection of these transcripts 
as immediately following infection and cell washing. We hypothesized that these transcripts 
were not de novo transcribed, but were rather virion associated, as has been previously been 
shown for B-cell infection with B95.8 [263].  
De novo viral transcription begins 4 to 8-hpi for LMP-1 and 2 to 4-hpi for EBNA-2  
  During EBV infection, the virus must attach to the cell, fuse with the cellular 
membrane, uncoat the viral capsid, and be chaperoned to the nucleus. Only then, when the 
viral DNA reaches the nucleus, can transcription of viral genes begin. This process is not 
immediate, as it likely relies on cellular signaling and changes to the cytoskeletal apparatus. 
However, we can detect viral transcripts immediately upon infection and cell washing. 
Therefore, we wanted to understand the timing in which de novo transcription of the viral 
genome begins following T-cell infection. To do this, T-cells were treated with actinomycin 
D, a DNA polymerase inhibitor that blocks cellular transcription by preventing elongation of 
RNA during synthesis, 15 minutes prior to infection [266]. Therefore, based on differences in 
viral transcript levels in treated and untreated cells, we were able to determine when viral 
gene transcription begins through real-time PCR.  
We first analyzed the levels of transcripts for LMP-1, as they were the most abundant 
and most reliably detected following T-cell infection (Figure 2A). We observed the fold 
change of untreated compared to actinomycin D treated cells to consistently begin to rise 
beginning at 8-hpi, with a 1.9-fold higher expression in the untreated cells at this time-point. 
At 12-hpi, we observed a 2.8-fold higher expression. By 18-hpi, there was 12-fold higher 
expression in the untreated cells compared to the actinomycin D treated. This reached a peak 
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of 45-fold higher LMP-1 expression in untreated cells compared to treated cells at 23-hpi. 
This data suggests, that LMP-1 transcription begins around 4 to 8-hpi. 
EBNA-2 transcript levels were also compared in this experiment between 
actinomycin D treated and untreated cells (Figure 2B).  We observed slightly earlier 
transcription of EBNA-2 than LMP-1. The difference between treated and untreated cells 
began to consistently increase at the 4-hpi time-point, with a 3.2-fold higher expression in the 
untreated cells. This trend continued at 8-hpi, in which 8.3-fold higher expression of EBNA-
2 was observed in the untreated cells. By 12-hpi and 18-hpi, we observed 13.8-fold and 
124.9-fold higher expression, respectively. There was as high as a 630.9-fold difference in 
EBNA-2 expression between treated and untreated cells at 23-hpi. Based on this data, we 
suggest that de novo transcription of EBNA-2 begins between 2 to 4-hpi and the transcripts 
detected before these time points are virion associated. The next question we sought to 
answer was whether the virion associated transcripts were functional at being translated into 
protein.  
Virion associated RNAs translate LMP-1 protein 
Since LMP-1 was the highest expressed transcript and the LMP-1 protein from Jijoye 
has a relatively short half-life of 2 hours, we analyzed the protein expression of LMP-1 
within 24-hpi [267]. Due to the short half-life, we expected to have the ability to identify 
changes in protein levels in this time-frame. T-cells were infected with EBV-2 and harvested 
at 0, 1, 2, 4, 8, 12, 18, and 24-hpi and analyzed by western blot for expression of LMP-1 
protein. In the untreated cells, we detected LMP-1 protein at all time-points (Figure 3A). The 
level of this protein increased over time, through 24-hpi, suggesting that LMP-1 is being 
translated within 24 hours.  
	   61	  
Prior to infection, one set of purified T-cells was treated with the transcription 
inhibitor Actinomycin D, as was done for transcript analysis. For actinomycin D treated cells, 
we also observed LMP-1 protein at all time-points (Figure 3B). However, unlike untreated 
cells, we did not observe an increase in LMP-1 levels over time, but rather the levels 
remained constant. This suggests that de novo transcription is required for the increase in 
LMP-1 levels seen in the first 24-hpi.  
T-cells were also treated with cycloheximide prior to infection. Cycloheximide is a 
protein translation inhibitor that blocks translation elongation through binding the E-site of 
the 60S ribosomal subunit [268, 269]. In cells treated with cycloheximide, we observed 
LMP-1 protein at all time-points. However, by 8-hpi we observe an obvious reduction in 
LMP-1 levels (Figure 3C). This data, in total, shows that translation, but not transcription is 
required to sustain LMP-1 levels. Therefore, the virion associated transcripts are able to 
sustain these levels past the half-life of the protein and are being translated into protein.  
No difference in virion associated transcripts transferred to CD4 or CD8 T-cells 
 We have previously observed differences in the outcome of the infection of CD4+ 
and CD8+ T-cells by EBV-2. CD8+ T-cells are infected at a higher level, become more 
activated, and proliferate at a much higher level than CD4+ T-cells analyzed at 7-dpi [47]. 
Therefore, we sought to determine if there was any difference in the detection of virion 
associated transcripts or levels of those transcripts transferred to CD8 or CD4 T-cells. We 
analyzed the transcripts present following infection of purified CD4 and CD8 T-cells from 0 
to 4-hpi in which primarily only the virion associated transcripts should be present. However, 
in one experiment we did not observe any differences in the gene transcripts present in CD4 
or CD8 T-cells (Figure 4). Like total T-cells, there was detection of LMP-1, LMP-2, EBNA-
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1, and EBNA-2, but no detection of BZLF1, in both subsets. Furthermore, there was no 
difference in the levels of transcripts between these two cell subsets. This single experiment 
suggests that the difference in infection outcomes between CD4 and CD8 T-cells at 7-dpi are 
likely not mediated by differences in the transfer of virion associated transcripts.  
EBV-1 and EBV-2 virions are associated with different viral transcripts 
 The presence virion associated transcripts has only been explored following EBV-1 
infection of B-cells [263]. B-cell infection with EBV-2 results in a lower rate of 
transformation than infection with EBV-1 [265]. Therefore, we sought to determine if there 
are any differences in the virion associated transcripts present following the infection of B-
cells with EBV-1 and EBV-2. Purified B-cells were infected with either EBV-1 or EBV-2 
and viral transcripts were analyzed at 0, 1, 2, and 4-hpi. For EBV-1 infection, we were able 
to detect BZLF1 transcripts at the highest level and most reliably (Figure 5A). We were only 
able to detect low levels of LMP-1, LMP-2, EBNA-1, and EBNA-2 Conversely, we observed 
a similar pattern following EBV-2 infection of B-cells as we did with T-cell infection, in 
which the latent transcripts are more highly transferred (Figure 5B). LMP-1 and EBNA-2 
were expressed at the highest levels. LMP-2 and EBNA-1 were expressed at low levels. In 
contrast to T-cell infection, we did detect a small amount BZLF1 transcripts from one of the 
two donors by 4-hpi. This data suggests that different sets of viral transcripts are associated 
with EBV-1 and EBV-2 virions and transferred into infected B-cells. 
Discussion 
 In this study, we describe the early viral gene expression pattern following EBV-2 
infection of T-cells. Within 24-hours, we observed highest expression of LMP-1 and EBNA-
2 and lower expression of LMP-2 and EBNA-1. Furthermore, there is no detectable 
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expression of the lytic gene transcript BZLF1. Based on a single experiment comparing the 
levels of transcripts with and without treatment with the transcription inhibitor actinomycin 
D, we determined that EBNA-2 transcription began between 2 and 4-hpi for EBNA-2. LMP-
1 transcription began slightly later, as levels of transcripts were not affected by actinomycin 
D treatment until 8-hpi. Furthermore, these transcripts are functional and can be translated 
into protein, as treatment with the transcription inhibitor sustained LMP-1 protein levels, but 
treatment with a translation inhibitor did not. This suggests that translation, but not 
transcription is required to sustain these levels. Therefore, protein translation is not reliant on 
de novo transcription and virion associated transcripts are actively being translated. It is 
important to understand the function of these genes early in infection and their role in the 
outcome of infection.  
 It is still unclear the roles of these gene products in the early stages of T-cell 
infection. However, the two most highly expressed virion associated transcripts, LMP-1 and 
EBNA-2, have known functions in B-cells that could potentially alter the fate of infection. 
LMP-1 is a constitutively signaling CD40 mimic that signals to alter the survival and growth 
of expressing cells [35]. Furthermore, EBNA-2 is a major viral transcription factor that can 
promote expression of both viral and cellular genes [35]. This expression could play a role in 
driving the proliferation, activation, and cytokine expression that we observe following T-
cell infection [47]. However, little is known about the functions of these genes in T-cell 
infection or the gene expression requirements that facilitate successful T-cell infection with 
EBV-2.  
We have also shown in this study that that virion associated transcripts are EBV cell-
line dependent, as different transcripts were detected within 4 hours of B-cell infection with 
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EBV-1 compared to EBV-2. Most notably, we detected the lytic transcript BZLF1 at the 
highest levels and most consistently of following EBV-1 infection and only low levels of 
detection of any of the latent transcripts. Following EBV-2 infection we observed a similar 
pattern for B-cell infection as we did for T-cell infection, detection of LMP-1, LMP-2, 
EBNA-1, and EBNA-2. We did observe some detection of BZLF1, but much lower level 
than was detected for the latent transcripts and in EBV-1 infection.  
During primary infection of B-cells, EBV-1 has been shown to undergo a prelatent 
phase of infection [183, 257, 258]. This consists of expression of lytic genes, including 
BZLF1, but no production of infectious virus within the first few days of primary B-cell 
infection. This prelatent phase is thought to play two roles in LCL establishment.  The first, 
is to activate quiescent B-cells into going into the cell cycle, through BZLF1 [183]. Second, 
to prevent from immediate activation induced cell death, through the viral BCL-2 homologs, 
BALF1 and BHRF1 [270]. Previously, we have observed a reduced B-cell proliferation and 
higher levels of cell death following EBV-2 infection of B-cells, compared to EBV-1 
infection (E. Wohlford, R. Rochford unpublished observations). The data presented here 
suggests that there is a much lower transfer of virion associated BZLF1 in EBV-2 infection 
of B-cells, compared to EBV-1 infection. We hypothesize that this reduced level of BZLF1 
expression suggests a reduced prelatent phase of infection for EBV-2. This may play a role in 
the reduced ability for EBV-2 to immortalize B-cells in culture. It has been reported that high 
expression of LMP-1 in B-cells has a cytotoxic effect [271]. The higher levels of LMP-1 
following EBV-2 infection could also play a role in the higher level of cell death and poor 
transformation capacity of EBV-2.  
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Another question is what controls the packaging of these transcripts into the virion. It 
has been shown with other herpesviruses that viral RNAs are packaged preferentially over 
host cells and that these transcripts are packaged in similar proportions as they are expressed 
in the producing cell [262, 272-274]. Therefore, not only could the differences in viral gene 
expression play a role in modifying recipient cells, they may play a role as to what is 
packaged within the virion during production. EBNA2, through interactions with the cellular 
Ten-Eleven Translocation 2 (TET2), is involved in methylation of cellular and viral genes 
and is involved in the regulation of latency and lytic reactivation [275]. The difference that 
we observe between EBV-1 and EBV-2 within important viral transcription factors, like 
EBNA-2, may play a role in the differences in what is expressed in the virion producing cell. 
Furthermore, recently described differences in the BZLF1 promoter could play a role in the 
differential expression of this gene [44]. However, the variant common to EBV-2, V3, has 
been observed to induce higher levels of BZLF1, which contradicts what is observed in our 
study [45]. The importance of these differences in the resulting transcripts within the virion 
should be further explored.   
Previous reports on virion associated transcripts suggest a role for overcoming the 
gap between virus entry and de novo gene transcription. This seems to be important in the 
outcome in viral infection, as it is a conserved property among many herpesviruses. 
Therefore, the differences we observe between EBV-1 and EBV-2 in the viral associated 
transcripts may be important in the lower efficiency for EBV-2 to transform B-cells and the 
persistence of the virus in the population. It is important to understand the roles of the virion 
associated transcripts to provide insight into the ability to promote a persistent infection with 
EBV, both in vitro and in vivo.  




Figure 1. Detection of EBV latent, but not lytic transcripts within 24-hours of infection. 
Figure represents two individual donors (Black – Donor 1, Red – Donor 2) and the levels of 
mRNA transcripts of the latent genes LMP-1, LMP-2, EBNA-2, and EBNA-1 and the lytic 
transcript BZLF1, normalized to β2 microglobulin expression. Data is presented as ΔCt    





























































Figure 2. T-cells were left untreated or treated with the RNA transcription inhibitor, 
actinomycin D. Cells were harvested at 0, 0.25, 0.5, 1, 2, 4, 8, 12, 18, and 23-hpi and 
analyzed for viral gene expression and normalized to β2 microglobulin expression, Fold 
Change = 2^-([Untreated treated EBV gene Ct –β2 microglobulin Ct] – [Actinomycin D 
treated EBV gene Ct – β2 microglobulin Ct]). The fold change between untreated and 





















































Figure 3. Purified T-cells were A) untreated, B) treated with actinomycin D, or C) treated 
with cycloheximide prior to infection with EBV-2. Cells were harvested at 0, 1, 2, 4, 8, 12, 
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Figure 4. CD4 and CD8 T-cells were analyzed for the transfer of virion associated viral 
transcripts following infection with EBV-2. Cells were harvested and analyzed at 0, 0.5, 1, 2, 
and 4-hpi and analyzed for EBV gene expression. Transcripts detected in CD8 are 
represented in black and those detected in CD4 are represented in red. Data is shown as ΔCt 
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Figure 5. Purified B-cells were infected with A) EBV-1 or B) EBV-2. Cells were harvested at 
0, 1, 2, and 4-hpi and analyzed for EBV gene expression. Data is shown as ΔCt (ΔCt = EBV 
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CHAPTER IV 
DIFFERENCES IN THE ESPTEIN-BARR VIRUS GP350 IgA ANTIBODY 
RESPONSE ARE ASSOCIATED WITH INCREASED RISK FOR CO-INFECTION 





The EBV viral glycoprotein gp350 has been proposed as a candidate antigen for an 
EBV vaccine. However, the proposed formulations of these vaccines have not taken into 
account the presence of two unique EBV strains (EBV-1 and EBV-2) present in areas of high 
incidence of the EBV associated cancer, Burkitt’s lymphoma. 
Methods 
In this study, we analyze the kinetics of EBV-1 and EBV-2 infection in an 
asymptomatic infant cohort from Kisumu, Kenya. We also analyzed the kinetics of the 
antibody response against five EBV antigens, gp350 (IgG and IgA), VCA (IgG), EBNA-1 
(IgG), EA-D (IgG), and Zta (IgG). 
Results 
We observed a high frequency of co-infection with both EBV types over time, with 
the only observable defect in the antibody response in infants co-infected being a lower level 
of anti-gp350 IgA antibodies at peak response. IgA levels were also significantly lower in co-
infected infants 2.5 months post-infection and at the time of co-infection.  
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Conclusions 
These results suggest that anti-gp350 IgA antibodies may be important for sterilizing 
immunity against secondary infection. These findings have implications for the development 
of an efficacious EBV vaccine to prevent both EBV-1 and EBV-2 infection in a population at 
high risk for Burkitt’s lymphoma. 
Background  
Primary infection with Epstein-Barr virus (EBV) can occur early in childhood, 
generally resulting in asymptomatic infection, or later in adolescence, often presenting as 
acute infectious mononucleosis (AIM) [276, 277] By adulthood, infection is almost 
ubiquitous, with >95% of the population being EBV sero-positive [1]. EBV is associated 
with a number of human lymphoproliferative diseases and cancers, including endemic 
Burkitt’s lymphoma (eBL), one of the most common childhood cancers in Sub-Saharan 
Africa [278]. eBL has also been associated with repeated Plasmodium falciparum malaria 
infection, as incidence of this cancer is higher in malaria endemic regions [279-281]. 
Interestingly, living in malaria endemic regions has been shown to be a predictor of early age 
of EBV infection [232], a factor which has also been hypothesized to be associated with 
Burkitt’s lymphoma development [282-284].  
EBV has been classified into two unique strains, EBV type 1 (EBV-1) and type 2 
(EBV-2). This classification is driven by distinct genetic differences in key latency genes, 
specifically Epstein-Barr nuclear antigen (EBNA) -2, EBNA-3a, and EBNA-3c [37-42]. The 
genetic differences are linked to the reduced capacity of EBV-2 to transform B-cells in 
culture [38, 41, 49]. More recently, deep-sequencing of a large number of EBV isolates has 
revealed additional genetic differences in the lytic genes, BZLF1 and gp350, that flank the 
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EBNA-2 locus [43, 44]. In addition to the genotypic and phenotypic differences between 
EBV-1 and EBV-2, these two strains also have distinct geographic variations in their 
prevalence. EBV-1 has a global distribution while EBV-2 is localized to regions in Africa in 
healthy populations and an increased prevalence in HIV-positive populations [69]. In 
previously reported studies in Kenya, we have observed prevalence of both EBV-1 and EBV-
2 in children and adults [16, 46].  
Evaluation of the humoral response to primary EBV infection has been studied 
mostly in young adults presenting with AIM, a symptomatic disease [202, 203, 207].  For 
example, in a study of American college students with AIM, the peak IgG antibody response 
to the viral capsid antigen (VCA), a late lytic protein, was generated before the peak response 
to the EBNA-1 latent protein [202]. Interestingly, another study showed that higher levels of 
antibody against gp350 correlated to a significantly reduced severity of AIM [203].  
The viral glycoprotein gp350 binds the cellular CD21 or CD35 on the surface of the 
B-cell [84-86, 88, 285]. This interaction is required for B-cell infection. Antibodies to gp350 
have been shown to neutralize B-cell infection in vitro and are correlated to the neutralizing 
ability of human serum [204]. For these reasons, gp350 has been studied as an EBV vaccine 
candidate [220].  However, the kinetics of the anti-gp350 response has yet to be analyzed in 
primary infection in infants. In most studies, the IgG antibody response has been analyzed for 
gp350. However, because EBV is transmitted via saliva and breastmilk, primary infections 
occur in the oral pharynx [15, 16]. This suggests a potential role for IgA antibodies, which 
are more predominant in mucosal and respiratory surfaces, in protection against infection 
with EBV.  
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We have previously reported on a longitudinal study following EBV infection of 
infants from a malaria endemic region of Kenya with a high incidence of Burkitt’s lymphoma 
[232, 279]. This is a population in which a complete understanding of the humoral immune 
response would be extremely beneficial to understand the potential of an EBV vaccine. In 
this cohort, we have previously reported that malaria exposure is associated with a younger 
age of EBV infection, a higher rate of EBV expansion, and shortened time between EBV 
episodes [232, 286]. Furthermore, we have observed a more rapid decline of maternal IgG 
antibodies against VCA and EBNA-1 and longer lasting VCA-IgM antibodies associated 
with malaria exposure [199]. In this study, we investigate the viral types associated with 
these episodes and the gp350 antibody responses in the same cohort, and we seek to answer 
two important questions.  First, in infants with variable EBV load over time, what EBV 
genotype was present and second, what was the pattern of the gp350 IgG and IgA response.  
Here we present data from a longitudinal study in a malaria holoendemic region of Kenya, 
where primary EBV infection occurs early in life, and EBV-2 is prevalent, to determine the 
relationship between the two virus types following primary infection in infants. We also 
examined the antibody response against multiple EBV antigens, most importantly gp350, 
generated following primary asymptomatic infection, which has yet to be described in a 
similar population.  
Methods 
Study design and patient recruitment 
Samples were collected from study participants from a malaria holoendemic region, 
in which there is a high-risk for endemic Burkitt’s lymphoma. This study comprised a subset 
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of thirty-six infants that has been described in an earlier study [232]. The thirty-six infants in 
this analysis were included based on having three or more episodes of elevated viral load.  
Viral load and EBV typing 
DNA from whole blood was extracted using a QiaAmp DNA Mini Kit in accordance 
with the manufacturer’s protocol (Qiagen, Valencia, California). EBV DNA was quantified 
by quantitative polymerase chain reaction (qPCR) detecting the BALF5 region of the EBV 
genome and for human beta-actin, as described previously [232]. EBV typing was performed 
on the EBV genome positive DNA samples. The EBNA-3c region was amplified by 
polymerase chain reaction (PCR) as previously described [287]. PCR product size was 
analyzed by 2% agarose gel containing 5% ethidium bromide. EBV-1 samples amplified a 
PCR product of 153 base pairs and EBV-2 amplified a PCR product of 246 base pairs.  
Antibody detection 
VCA-IgG, anti-EBNA-1-IgG, anti-EA-D (Early antigen–diffuse)-IgG, and anti-Zta-
IgG response were detecting using a Luminex assay as previously described [200, 232]. At 
least 75 beads were analyzed for mean fluorescence intensity (MFI) for each EBV antigen.  
Anti-gp350 IgG and IgA antibody levels were determined by enzyme-linked 
immunosorbent assay (ELISA). We began by coating a 96-well plate overnight at 4°C with 
1µg/ml recombinant gp350 peptide (a.a. 4-450) (Immune-tech). This peptide contains the N-
terminal region known for CD21 binding and the epitope for the monoclonal neutralizing 
antibody, 72A1. Plates were then blocked with 3% bovine serum albumin (BSA) in PBS for 
1 hour at 37°C. The blocking solution was removed and plasma, diluted 1:100 in 0.05% 
Tween-20, 3% BSA in PBS, was then added to the plate. Plasma was incubated for 1 hour at 
37°C. Plates were then washed extensively with 0.05% Tween-20 in PBS. A 1:10,000 
	   76	  
dilution of goat anti-human IgG – horseradish peroxidase or 1: 2,000 goat anti-human IgA – 
horseradish peroxidase in 3% BSA in PBS was added to the plates and incubated for 1 hour 
at 37°C. Plates were again washed and incubated with TMB substrate for 10 minutes before 
being stopped with 1M H3PO4. Plates were read for absorbance at OD450 on a Versamax 
microplate reader. OD450 was calculated using the mean of duplicate values for each plasma 
sample and subtracting the mean of four replicate wells with no serum, only sample dilution 
buffer, plus 3 times the standard deviation.  
Statistical analysis 
The statistical analysis of peak responses was performed using Graphpad Prism 
version 6.0 (La Jolla, CA). Comparisons of antibody response and neutralization between 
single infected and co-infected groups were done using the Mann-Whitney test, due to only 
13 samples in the co-infected group. A p-value ≤ 0.05 was considered statistically significant.  
Piecewise linear models were fit to log transformed OD450 values for gp350 IgA and 
gp350 IgG to test for differences in antibody response to test for differences in antibody 
response between single and co-infected infants [288]. Since the observed antibody response 
was characterized by a rapid increase post-initial infection followed by a leveling off of 
antibody production (seen through smoothing splines, Supplementary Figure 1), our 
objective was to estimate these slopes separately. Piecewise linear models allow for slopes to 
differ between infection type both before and after the breakpoint (where antibody response 
over time levels off), allowing for hypotheses related to infection type and antibody response 
to be tested. The ‘segmented’ package in R (R Foundation for Statistical Computing, Vienna, 
Austria) was used to estimate an individual breakpoint for each outcome where each estimate 
was calculated using the combined infection type data, allowing for the same breakpoint but 
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different slopes based on infection type [289, 290]. A piecewise linear mixed model was used 
to account for correlation among repeated measures from the same subjects in SAS 9.4 
(Cary, NC) with a spatial power covariance structure (due to irregular repeated 
measurements and differences in age at first detected infection) [288]. Time was normalized 
to zero for each subject based on first detection of virus via PCR. The final models included a 
binary factor for infection type, continuous time, a binary indicator for before and after the 
breakpoint, and interactions between these three variables to estimate slopes for each 
infection type prior to and after the breakpoint. Age at baseline was also included. Estimate 
statements in SAS were used to test for differences in infection type via t-test. Final plots 
were generated using R.    
Results 
Study population 
We have previously reported on this infant cohort from Kisumu, Kenya where we had 
noted that following primary EBV infection the viral load had multiple peaks over time [199, 
232].  Of the original 68 infants evaluated, we identified 36 infants that had multiple peaks of 
EBV viral load in the blood within the first thirty months of age (Figure 1A, Supplementary 
Figure 2) [232].  The mean age of EBV infection in the 36 infants was 7.8 months (0.48 
SEM) and not significantly different than the mean age of EBV infection in the entire cohort 
[7.3 months (0.33 SEM)]. Gender was also similar to the full cohort (38.8% male and 42.6% 
male, subset and full cohort, respectively). 
Because EBV-2 has previously been detected in Kenya [16, 46, 73], we reasoned that 
the peaks of viral load could be due to either a secondary infection with a different EBV 
strain or virus reactivation from latency.  To test the EBV genotypes in the blood, we used a 
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PCR assay to distinguish EBV types based on a defined deletion in the EBNA-3c gene 
(Figure 1A). This PCR was performed on all EBV-PCR positive samples from each infant. In 
total, we had an average of 6.4 EBV+ time-points per infant. At the initial detection of EBV 
in the blood, 22 infants were EBV-1
+
 (61.1%), 11 infants were EBV-2
+
 (30.6%), and 3 
infants were co-infected (8.3%).    
When EBV type was analyzed over the entire study, 12 infants remained EBV-1+ at 
all time-points (33.3%), 8 infants were only EBV-2+ (22.2%), while 16 infants had evidence 
of EBV-1 and EBV-2 co-infection at any given time throughout the study (44.4%; Figure 
1B).  While some of the peaks in infants with only one EBV type could be due to virus 
reactivation or secondary infection with the same type, 13 out of 36 infants (36.1%) showed 
direct evidence of secondary infection with a different EBV type. Therefore, we sought to 
determine the development of the EBV specific antibody response to understand this lack of 
sterilizing immunity against a secondary infection.  
Reduced anti-gp350 IgA antibodies at peak response in co-infected infants 
To evaluate the peak of EBV antibody responses in infants that were only infected 
with a single detectable EBV type (n=19) compared to infants that were co-infected (n=13), 
we evaluated the peak levels of VCA-IgG, EBNA-1-IgG, EA-D-IgG and Zta-IgG following 
primary EBV infection. The kinetics of these responses were measured for thirty-four of the 
thirty-six original infants, including two that were initially co-infected, due to the availability 
of plasma samples for all assays and sufficient time points These data were generated using a 
luminex bead based array and the results are expressed as mean fluorescence intensity (MFI) 
for antibody levels.  As shown in Figure 2A, we observed no differences in peak IgG to any 
of the measured EBV antigens.  
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gp350 is the proposed EBV vaccine candidate and antibody levels in serum have been 
correlated to neutralization, in vitro [204, 220]. Therefore, we next evaluated gp350-IgG and 
gp350-IgA present in infant plasma samples. We compared the antibody response of infants 
following primary infection with a single type over the length of the study (n=19) to those 
that started with one EBV type and acquired a secondary infection (co-infected, n=13).  The 
mean peak magnitude of these antibody responses for the group infected with a single EBV 
type was an OD450 of 1.15 for gp350-IgG and an OD450 of 1.76 for gp350-IgA. For the infants 
acquiring a secondary infection, there was a mean OD450 of 1.02 for gp350-IgG and an OD450 
of 1.03 for gp350-IgA (Figure 2B). Interestingly, the peak magnitude of anti-gp350-IgA but 
not the anti-gp350-IgG antibodies was significantly lower in infants that were co-infected 
compared to those only infected with one type (p=0.049).  
We next analyzed the timing of the antibody response from initial virus detection to 
peak response, comparing infants infected with one type of virus and those infected with 
multiple types. The average time to peak antibody response for infants infected with a single 
type of EBV occurred 10.9 (gp350-IgG), 9.4 (gp350-IgA), 9.6 (VCA-IgG), 11.8 (EBNA-1-
IgG), 9.1 (EA-D-IgG,), and 7.3 (Zta-IgG) months following first PCR detection of virus 
(Figure 2C). For infants that acquired a secondary infection of a different type, the average 
time to peak response was 11.1 (gp350-IgG), 12.4 (gp350-IgA), 10.8 (VCA-IgG), 13.2 
(EBNA-1-IgG), 8.5, (EA-D-IgG,) and 7.9 (Zta-IgG) months following first detection of 
virus. There was no significant difference in the time to the peak response between infants 
infected with one EBV type compared to infants infected with both EBV types (Figure 2C). 
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Modeling anti-gp350 antibody response in asymptomatic infants 
Because the only observable difference in the antibody response between infants 
infected with a single type of EBV compared to those infected with multiple types was a 
reduction in the anti-gp350 IgA magnitude at the peak of the response in those that acquired 
a secondary infection, we wanted to evaluate these responses longitudinally using a 
piecewise linear model (Figure 3A). The piece-wise linear model generates two slopes, 
representing two distinct phases of the response. These two slopes meet at a breakpoint, 
which might indicate the change from the first to the second phase of the response over time. 
The gp350-IgA and gp350-IgG models were analyzed at 0, 2.5, 5, 6.4 (average time of co-
infection) 10, and 15 months post-infection. The models were also compared at the 
breakpoint, 8.4 and 6.7 months post infection, for IgA and IgG, respectively. We also 
compared the slope of the line, which represents the rate of change in antibody levels, before 
and after the breakpoint. We observed no statistically significant difference in any 
comparison performed for gp350-IgG (Figure 3B). However, for gp350-IgA, we observed 
that the co-infected infants had log(IgA) levels that were significantly lower than the single 
type infected infants at 5 months and at the average age of co-infection (6.4 months) (p≤0.05) 
and marginally significant lower levels at 2.5 months and the breakpoint (8.4 months), 
p=0.058 and p=0.052, respectively. Interestingly, there was no difference in the slopes of the 
line, either before or after the breakpoint (Figure 3B). This further suggests that the anti-
gp350 IgA response was diminished in the infants that acquired a secondary infection with a 
different EBV type, although the lack of statistical significance could also be the result of a 
small sample size.  
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Discussion 
Since the first description of the second strain of EBV, few studies have characterized 
the natural history of EBV-2. This is the first longitudinal study to evaluate the acquisition of 
EBV type following primary infection in infants in a region where both types of EBV are 
common. Our study revealed a high prevalence of co-infection with both EBV types and 
evidence that a primary infection with one EBV strain did not prevent infection with the 
second strain. Importantly, we found that secondary infection occurred in infants with a 
lower level of anti-gp350 IgA antibodies, but not anti-gp350 IgG, in plasma at peak response, 
suggesting that co-infection occurred in infants that failed to mount an adequate IgA immune 
response to gp350, the EBV glycoprotein critical for viral entry in B-cells.   
In this study, we analyzed the EBV genotype at each EBV+ time-point for 36 infants 
that had shown to have multiple peaks of viral load in a previous analysis [232]. These 
infants could have also been characterized as “poor controllers”, defined as having an EBV+ 
time-point 3 months or longer after primary infection [291]. Interestingly, we observed a 
high frequency of co-infection with both types of EBV (44.4%).  In contrast, a cohort in the 
UK showed only 6% co-infection, however the frequency of EBV-2 is much lower in this 
population [292]. Co-infection was much higher, 50-60%, in an HIV+ cohort from the 
Netherlands, consistent with a higher overall frequency of EBV-2 in HIV infection [69]. An 
earlier study in Kenya and Papua New Guinea that relied on LCL outgrowth, rather than PCR 
based methods, showed no evidence of co-infection [73]. However higher frequencies of co-
infection are observed when PCR methods are used, rather than tumor samples or LCLs 
[293]. It is possible that our longitudinal cohort, taking into account the type at all time-
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points, compared to a cross-sectional study, revealed a higher frequency of co-infection that 
is more indicative of this population.  
Serum antibody titers against gp350 have been shown to be the most correlated to the 
ability for serum to neutralize EBV infection of B-cells [204]. In this study, we observed a 
reduced level of anti-gp350 IgA levels at peak response in infants with co-infection with two 
EBV types, compared to those that were infected with a single EBV type.  In a study of EBV 
seropositive healthy adults or patients with AIM from Canada, there was no detection of anti-
gp350 IgA antibodies in the serum [207]. However, in this study, we observed this response 
in all infants tested following asymptomatic primary infection. Anti-gp350 IgA antibodies 
have also been shown to enhance the infection of polarized epithelial cells, but neutralize B-
cell transformation [93]. Interestingly, elevated anti-gp350 IgA antibodies have been shown 
to be a risk factor for nasopharyngeal carcinoma [208]. These antibodies have been suggested 
to have a potential pathogenic role in epithelial cell infection and diseases of this cell-type 
[209]. However, our data suggests they can be helpful in protection against co-infection. This 
suggests a potential role for serum IgA antibodies for protection against B-cell infection, but 
a less protective role in the mucosa, where EBV may first infect epithelial cells. 
A comparable longitudinal study analyzed the kinetics of the anti-EBV humoral 
immune response in American college aged individuals with AIM [202]. They reported a 
delay of 333 days after presentation of symptoms before peak anti-gp350 IgG response by 
ELISA. We observed almost identical timing for the development of peak anti-gp350 IgG 
levels in the plasma (334.5 days post infection). Another study focusing on AIM showed a 
biphasic response [203], which was not consistently observed in our study However, it is 
possible because we only evaluated antibody levels through three years, we may not have 
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seen a similar response. Furthermore, we observe more incidences of recurring viral load, 
compared to what is typically seen post-AIM. EBNA-1 responses have been shown to be 
delayed due to limited access for class II MHC processing and delayed CD4+ T-cell 
responses [198]. Consistent with this, a previous longitudinal cohort of college aged adults 
that showed a delayed response for EBNA-1 IgG, compared to VCA IgG, similar to what we 
see in our study [201]. Overall, we observed the pediatric antibody response observed in this 
study to be relatively similar to that of adults with AIM for VCA IgG, gp350 IgG, EBNA-1 
IgG.  
Due to constraints of the volume of sample that was collected from infants, we could 
not distinguish a secondary infection with the same type of EBV from reactivation. This 
could be done in future studies by sequencing more variable regions of the EBV genome, 
including latent membrane protein 1. We did observe a secondary boost of antibody response 
against EA-D and Zta in some infants, potentially indicative of reactivation [200]. However, 
this was not consistent among all study participants infected with a single EBV type. Another 
limitation of this study was the small sample size, which made it difficult to detect 
differences in the slopes that appeared to be evident post-breakpoint in Figure 3A.  
The EBV gp350 protein is a target for an EBV vaccine [220]. However, as EBV is 
transmitted through saliva, an IgA response is likely to be critical in protection against 
infection.  This is supported by our data where we found a significantly lower level of anti-
gp350 IgA in infants that acquire infection with a second strain of EBV. The role of gp350 
IgA antibodies to protect against secondary infection and a potential role in the development 
of an efficacious EBV vaccine should be further explored.  
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Figure 1. A) Four representative time courses from four individual infants showing viral load 
(copies/µg) and EBV type over time (months).  Time courses for all 36 infants are shown in 
Supplementary Figure 2.  Black (EBV-1), gray (EBV-2), black/gray (co-infection), white 
(EBV detected, no type), and X (No EBV detected). B) Compiled data for all 36 infants. The 
left chart represents the EBV type at initial detection of virus. The chart on the right 
represents the EBV type at all time points for each individual infant over time. Black (EBV-
1), gray (EBV-2), and white (co-infection). n=36 
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Figure 2. A) Analysis of the magnitude of the antibody response at the peak level post-
infection measured by Luminex, comparing single type infected infants (n=19) with co-
infected infants (n=13). (VCA IgG; p=0.821, EBNA-1 IgG; p>0.999, EA-D IgG; p=0.238, 
Zta IgG; p=0.677) B) Analysis of gp350 antibody response by ELISA, comparing single 
infected (n=19) to co-infection (n=13) (gp350 IgA; p=0.049, gp350 IgG; p=0.430) C)   
Analysis of the time from initial EBV detection to peak response comparing infants infected 
with a single type (n=19) with infants showing co-infection (n=13) in months. (gp350 IgG; 
p=0.570 gp350 IgA; p=0.094, VCA IgG; p=0.630, EBNA-1 IgG; p=0.603, EA-D IgG; 
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Figure 3. A) Piecewise linear model of log transformed ELISA data for gp350 IgA (left) and 
gp350 IgG (right). Time was normalized to 0 as initial detection of EBV by PCR. B) 
Statistical analysis comparing infants with a single EBV type, single infection (n=19) and co-
infection (n=13). Estimate statements were generated using SAS and reported with a 95% 

































Single	vs.	Co-infection Single	Type Co-infection p-value Single	Type Co-infection p-value
-1.94 -2.44 -2.39 -2.58
(-2.75,	-1.13) (-3.35,	-1.53) (-3.15,	-1.63) (-3.38,	-1.68)
-1.23 -1.8 -1.15 -1.39
(-1.61,	-0.86) (-2.25 ,-1.35) (-1.50 ,	-0.80) (-1.82, 	-0.97)
-0.73 -1.36 -0.64 -0.99
(-1.09,	-0.38) (-1.79 ,	-0.92) (-0.99, 	-0.28) (-1.43 ,	-0.55)
Average	time	of	Co-infection -0.45 -1.11 -0.35 -0.76
(6.4	months) (-0.83 ,	-0.07) (-1.58, 	-0.64) (-0.75 ,0.05) (-1.25 ,	-0.28)
Breakpoint -0.05 -0.76 -0.29 -0.72
(IgA	–	8.4	and	IgG	–	6.7	months) (-0.50,	0.39) (-1.32, 	-0.20) (-0.70,0.12) (-1.22,	-0.22)
-0.07 -0.64 -0.24 -0.55
(-0.47, 	0.33) (-1.14, 	-0.15) (-0.60 ,	0.10 ) (-0.97 ,	-0.13)
-0.13 -0.28 -0.20 -0.31
(-0.49 ,	0.23) (-0.77, 	0.21) (-0.54 ,	0.14) (-0.77, 	0.14)
0.20 0.18 0.20 0.16
(0.13	–	0.27) (0.09	–	0.26) (0.14	–	0.27) (0.08	–	0.24)
-0.01 0.073 0.01 0.05
















Supplementary Figure 1. Smoothing splines were applied to the log transformed data after 
stratifying by infection type using Graphpad. The observed trend in the data as well the trend 
of the splines helped provide the motivation for using a piecewise linear model framework to 
examine repeated measurements on subjects. The figures are displayed as log transformed 
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Supplemental Figure 2 
Study ID 1
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Supplemental Figure 2 (Continued) 
Study ID 19
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Supplementary Figure 2. Kinetics of EBV infection for each infant included in this study 
showing viral load (copies/µg) by time (months). Black (EBV-1), gray (EBV-2), black/gray 
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CHAPTER V 
PLASMA ENHANCEMENT OF EBV-2 INFECTION 
Abstract 
 Understanding the ability for antibodies to neutralize Epstein-Barr virus (EBV) 
infection is important for the development of an EBV vaccine. Historically, however, the 
assays used have measured the ability for EBV to transform B-cells in vitro or the 
measurement of infection using marker viruses. These methodologies have effectively 
excluded the study of the neutralization of isolates of a less common strain of EBV, EBV 
type 2 (EBV-2), due their poor transformation ability and the lack of a marker virus. Using a 
recently described qPCR based neutralization assay of EBV cord blood mononuclear cell 
(CBMC) infection, we show that plasma generated against infection with EBV-1 and EBV-2 
from Kenyan infants neutralizes EBV type 1 infection. The level of neutralization correlated 
with the level of anti-gp350 IgG and IgA antibodies in the serum. However, EBV-2 infection 
of CBMCs was enhanced by incubation with plasma, independent of the EBV type infected 
with. Upon further analysis, we determined that this enhancement was only observed in T-
cell infection, as B-cells were effectively neutralized. Furthermore, this enhancement 
occurred using both Kenyan infant plasma and plasma from North American adults. This 
intriguing result suggests that the antibody response generated against infection with either 
EBV type will still allow for infection of T-cells with EBV-2, in vitro. The role of this in 
vivo has not been explored, however it suggests that a secondary infection with EBV-2 could 
be skewed to the T-cell compartment, increasing risk of EBV associated T-cell diseases.  
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Introduction 
Epstein-Barr virus (EBV) is a nearly ubiquitous human pathogen that establishes 
persistent infection for the life of the host [1]. Most primary infections are asymptomatic, but 
in some cases, infection causes the self-limiting disease, infectious mononucleosis [2]. EBV 
is also the driving factor in a number of lymphoproliferative diseases and cancers. This 
includes cancers of B-cell origin, including Burkitt’s lymphoma and Hodgkin’s lymphoma, 
epithelial cell origin, including gastric carcinoma and nasopharyngeal carcinoma, and T-cell 
origin, including chronic active EBV and hydroa-vaccinoforme like lymphoma [3, 4, 7-9, 
11]. The development of an EBV vaccine is being explored to prevent these EBV associated 
diseases and the generation of neutralizing antibodies is crucial to an efficacious vaccine 
[220].  
Glycoproteins involved in entry are common targets of vaccines that prevent infection 
with other viruses. EBV infection of B-cells is mediated by interactions between the viral 
gp350 and the cellular receptors CD21 (complement receptor 2) or CD35 (complement 
receptor 1) [84-88]. Neutralizing antibodies in the plasma of are most correlated with gp350 
antibodies [204]. More specifically, anti-gp350 IgG1 antibodies have been shown to 
primarily mediate both antibody neutralization and antibody mediated phagocytosis by 
monocytes [205]. We have also shown that lower levels of gp350-IgA antibodies in plasma 
are associated with co-infection of EBV with the two EBV strains, EBV type 1 (EBV-1) and 
EBV type 2 (EBV-2) (Chapter 4). Therefore, EBV vaccine efforts have been focused on 
developing a gp350 specific response antibody response.  
The designs of these vaccines have been focused against the more common EBV-1 
strains and the ability to neutralize EBV-1 infection. There is, however, a more 
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geographically restricted strain of EBV that has not been considered in vaccine efforts, EBV-
2. EBV-2, despite its in vitro B-cell transformation deficiencies, is oncogenic in vivo and 
important to consider [38, 41, 73]. Furthermore, EBV-2, unlike EBV-1, latently infects 
primary T-cells in vitro, and infects T-cells in healthy children in Kenya [46, 47]. 
Importantly, we have shown that there are distinct genetic differences between EBV-1 and 
EBV-2 in the N-terminal CD21 binding region of gp350, where neutralizing antibodies 
would be targeting (Chapter 2) [44]. Like B-cell infection, we have shown that gp350 
binding CD21 is also required for infection of peripheral T-cells with EBV-2, in vitro 
(Chapter 2). Therefore, we have hypothesized that the differences in gp350 between these 
two virus types are important for the unique ability of EBV-2 to infect T-cells. Potentially, 
these differences could also alter the ability for neutralizing antibodies to block EBV-2 
infection.  
Classically, studies analyzing neutralization have relied on B-cell transformation or 
GFP marker viruses as the primary assay read-out [204, 294, 295]. Therefore, EBV-2 isolates 
have been excluded due to their poor transformation capacity and the lack of a marker virus. 
No studies to date that have used EBV-2 strains for in vitro neutralization assays to 
determine the ability for plasma antibodies to neutralize infection. In this study, we sought to 
understand if the differences between EBV-1 and EBV-2 play a role in antibody 
neutralization. We have adapted a qPCR based neutralization assay from Weiss and 
colleagues to incorporate both EBV-1 and EBV-2 strains [205]. We have also used plasma 
from EBV-1 and EBV-2 infected infants from a previous study malaria holoendemic region 
of Kenya to test the neutralizing ability of antibodies generated against infection with both 
EBV types (Chapter 4).  
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Methods 
Study participants 
 Kenyan plasma samples were collected from study participants from a malaria 
holoendemic region of Kenya, in which there is a high-risk for Burkitt’s lymphoma and a 
high prevalence of EBV-2 [232]. The EBV type, gp350-IgG, and gp350-IgA antibody levels 
were reported in a previous study (Chapter 4). North American plasma and peripheral blood 
mononuclear cells (PBMCs) were collected from adult participants at the University of 
Colorado, Anschutz Medical Campus. Cord blood was acquired from ClinImmune (Aurora, 
CO). Sample collection was approved by the Institutional Review Board of the University of 
Colorado, Anschutz Medical Campus and the Declaration of Helsinki and given with 
consent.  
gp350 IgG and IgA antibody detection 
 gp350-IgG and gp350-IgA antibody levels in plasma were measured by enzyme 
linked immunosorbent assay (ELISA). A 96-well high binding plate was coated with 1µg/ml 
recombinant gp350 peptide at 4°C overnight. This peptide contains the N-terminal CD21 
binding region, encompassing amino acid 4-450, and contains the epitope for the neutralizing 
monoclonal antibody 72A1 [244] (Immune-tech). Plates were blocked with 3% bovine serum 
albumin in PBS for 1 hour at 37°C. After removing blocking solution, plasma diluted 1:100 
in 0.05% Tween-20, 3% BSA in PBS was added and incubated for 1 hour at 37°C. Plates 
were washed with 0.05% Tween-20 in PBS. A 1:10,000 dilution of goat anti-human IgG-
horseradish peroxidase or a 1: 2,000 dilution goat anti-human IgA-horseradish peroxidase 
secondary antibody was added to the plates, depending on the antibody subtype of interest. 
The secondary antibody was incubated at 37°C for 1 hour and then washed extensively. TMB 
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substrate was then added to the plate for 10 minutes before stopping the color change 
reaction with 1M H3PO4. Plates were read on a Versamax microplate reader for OD450. OD450 
was calculated from the mean of duplicate values for each plasma sample. The mean of four 
replicate wells with no serum, only sample dilution buffer, plus 3 times the standard 
deviation was subtracted. 
Cell isolation 
Ficoll-Paque (GE Healthcare) was layered under peripheral blood. This density 
gradient allowed for the isolation of PBMCs and plasma. PBMCs were used for assays or 
specific cell isolation. B-cells were isolated by negative selection using the Pan B-cell 
isolation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany). T-cells were enriched as the 
non-B-cell fraction during B-cell isolation. Plasma was collected and store at -80°C. 
Cell purity analysis 
Cell purity for each isolated fraction was determined by flow cytometry. Cells were 
washed in flow cytometry buffer (PBS, 0.05% bovine serum albumin, 2mM EDTA). Cells 
were Fc blocked for 20 minutes and then stained with CD3-FITC and CD19-PerCp-Cy5.5 
antibodies.  Cell fractions were analyzed for the percentage of CD3+ T-cells and CD19+ B-
cells using specific antibodies. Flow cytometry was run on the BD Fortessa X-20 (BD 
Biosciences). Flow cytometry data was analyzed using FlowJo 10 software (TreeStar).  
Virus production 
 Virus isolated from two EBV+ cell lines were used for this study, the EBV-1 isolate 
B95.8 and the EBV-2 isolate Jijoye. Cells were grown in complete RPMI (RPMI with 10% 
fetal bovine serum, 1% Penn-Strep, and 1% L-Glutamine). Both viruses have previously 
been shown to infect B-cells, but Jijoye, not B95.8, has the ability to infect T-cells [47]. 
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Virus stocks were generated as previously described [234]. In brief, cells were treated with 
4mM sodium butyrate and 25ng/ml tetradecanyl phorbol acetate for induction of lytic 
reactivation. 5-days post induction, cell debris was removed by centrifugation at 4,000g for 
10 minutes at 4°C and any remaining debris was filtered from supernatant through a 0.45µm 
filter. Virus particles were then pelleted at 16,000g for 90min at 4°C. Virus was resuspended 
in 1/200 volume of complete RPMI with 100µg/ml bacitracin. DNase resistant viral genomes 
were quantitated in concentrated virus stocks by qPCR using primers and probes specific to 
the BALF5 region of the EBV genome, as described [232]. A multiplicity of infection (MOI) 
of 5 was used for all experiments.  
Neutralization assay 
 A qPCR neutralization assay was performed using both EBV-1 and EBV-2 viruses, 
adapted from a protocol described by Weiss and colleagues [205]. 5x10
6
 DNase resistant 
copies of EBV virus, either Jijoye or B95.8 were incubated with a 1:200 dilution of plasma in 
100µl complete RPMI at 37°C for 2 hours. As a neutralization control, 10µg of anti-gp350 
neutralizing antibody (clone 72A1) was incubated with virus [235]. Virus with no antibody 
or plasma was run for each cell type and experiment. After incubation, the virus/plasma 
mixture was added to 1x10
6
 cells in a total of 200µl complete RPMI. CBMCs, PBMCs, B-
cells, and T-cells were all used in this assay separately. After another 2-hour incubation at 
37°C, the cells were washed 3 times in PBS to removed free virus. Cells were then incubated 
for 3 days. 3-days post infection, cells were again washed 3 times with PBS. Viral load was 
quantitated using the BALF5 qPCR assay, run in duplex with a B-actin control for DNA 
input, as previously described. Viral load of infection with plasma was normalized to viral 
load with uninhibited virus. Each condition was run in triplicate. 
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Statistical analysis 
 Statistical analysis was done using Prism 6 software (GraphPad). Comparison of 
EBV-1 and EBV-2 initially infected infants and the single and co-infected infants was done 
using a Mann-Whitney comparison, as not all groups had greater than 15 data points. 
Correlations between % neutralization and gp350 antibody levels were performed by linear 
regression analysis. A p value ≤ 0.05 was considered statistically significant. 
Results 
gp350-IgG and gp350-IgA is equivalent in plasma by EBV type and infection pattern 
In Kenya, there is a high prevalence of both EBV-1 and EBV-2 and a high frequency 
of co-infection with both types (Chapter 4) [16, 46, 73]. However, the neutralizing ability for 
plasma, with consideration to the EBV type infected with, has not been explored. Previous 
studies have been performed using plasma samples from EBV-1 predominant regions and 
virus type has not been considered [204, 205]. In a previous study using this cohort, we have 
typed the virus in the blood of 36 infants and determined the levels of gp350-IgG and gp350-
IgA antibodies over the first three years of life (Chapter 4). In this study, plasma samples 
averaging 18.3 months of age (16.01-21.23 months) were used for neutralization. There was 
no difference in the gp350-IgG and gp350-IgA based on the original EBV type the infant was 
infected with (Figure 1A). In addition, there was no difference in these antibody levels in the 
plasma if the infant was infected with a single EBV type or co-infected with both types over 
the length of the original study (Figure 1B). Importantly, co-infection was detected at or 
before this time-point for all infants (Chapter 4). Therefore, differences in antibody levels 
between these groups would not play a role in any differences in neutralization observed.  
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Kenya plasma neutralization of CBMC infection by EBV-1 correlates to gp350 IgG and IgA 
 In this study, we performed a qPCR based neutralization assay of CBMCs to test the 
ability of plasma from EBV-1 and EBV-2 infected Kenyan infants to block infection. To 
analyze the neutralization ability against EBV-1, we used the prototypical strain B95.8 
(Figure 2A). As a neutralization control, we used the anti-gp350 monoclonal antibody clone 
72A1, which has been shown to neutralize EBV infection [235]. All but one sample, study ID 
28, neutralized EBV-1 infection. We did not observe a difference in percent neutralization 
between infants initially infected with EBV-1 and those initially infected with EBV-2 in their 
ability to neutralize EBV-1 (p=0.0792) (Figure 2B). Furthermore, there was no statistical 
difference in neutralizing ability between infants infected with a single EBV type over time, 
compared to those that acquired a co-infection in our previous study (p=0.8446) (Figure 2C). 
Interestingly, there was a statistically significant correlation between the neutralization 
ability between both gp350-IgG and gp350-IgA antibodies in plasma and the % 
neutralization observed in this assay (p=0.0070 and p=0.0043, respectively) (Figure 2D and 
2E). The correlation to gp350-IgG has been seen in previous studies and supports the 
reliability of our assay [205]. However, the correlation to gp350-IgA is a novel finding. We 
next employed this assay to test the neutralization against EBV-2 strains.   
Kenyan plasma enhances EBV-2 infection of CBMCs 
 For EBV-2 neutralization, we used the Jijoye strain. In this assay, 73% (16/22) of the 
Kenyan plasma samples either did not neutralize or enhanced EBV-2 infection of CBMCs 
(Figure 3A). Importantly, the monoclonal anti-gp350 neutralizing antibody still neutralized 
EBV-2 infection of CBMCs, suggesting this effect was specific to plasma and the assay was 
consistently reliable with EBV-2. Plasma from infants initially infected with both EBV-1 and 
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EBV-2 enhanced infection with EBV-2 virus equally (p=0.9229) (Figure 3B). Similarly, 
there was no statistical difference in percent neutralization between infants that were infected 
with a single type to those that acquired a co-infection (p=0.4558) (Figure 3C). In contrast to 
EBV-1 neutralization, the enhancement of EBV-2, was not significantly correlated to the 
levels of gp350-IgG or gp350-IgA levels in the plasma (p=0.1315 and p=0.9322, 
respectively) (Figure 3D and 3E). In total, Kenyan infant plasma was successful in 
neutralizing EBV-1 infection of CBMCs, but enhanced EBV-2 infection. We next sought to 
further understand this enhancement effect.  
Plasma enhancement is specific for T-cell infection, but not for CBMCs or Kenyan plasma 
 We wanted to answer three questions about this plasma enhancement of EBV-2 
infection. 1) Is this enhancement effect specific to the infection of CBMCs? 2) Was this 
effect specific to plasma from a Kenyan infant population? 3) Since EBV-2, unlike EBV-1, 
can infect primary T-cells, is this effect specific to one cell type?  Therefore, we adapted the 
qPCR based neutralization assay and adapted it for PBMCs. In parallel, we enriched for 
either B-cells or T-cells. We then incubated the virus with plasma from three North 
American adult donors (NA Donor 1-3) or three EBV-1 infected Kenyan infant plasma 
samples (Study ID 2, 6, and 11), all of which showed enhancement for CBMCs (figure 3A). 
We selected EBV-1 infected Kenyan infants because it is presumed that North American 
donors are most likely EBV-1 infected. However, viral load in North American adults is too 
low to test peripheral blood for EBV type. Similar to CBMCs, we observed enhancement of 
EBV-2 infection in total PBMCs with all but one plasma sample, Study ID 11 (Figure 4A). 
However, in the B-cell enriched population, we observed neutralization of infection with all 
of the plasma samples (Figure 4B). Interestingly, all 6 plasma samples enhanced infection of 
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the T-cell enriched fraction (Figure 4C). The enhancement of EBV-2 infection occurred with 
plasma from both the Kenyan infant population and the North American adult population, 
suggesting no age or population dependence on this effect. Most interestingly, the 
enhancement only occurs with infection of T-cells.  
Discussion 
 In this study, we sought to understand the ability of plasma antibodies generated in 
response to infection with either EBV-1 or EBV-2 to neutralize infection with viruses of both 
EBV types, in vitro. First, we used a qPCR based neutralization assay to measure infection of 
CBMCs with or without incubation of virus with plasma from Kenyan infants. EBV-1 
infection was neutralized the same by plasma from infants initially infected with EBV-1 or 
EBV-2 and infants that were infected with a single EBV type or co-infected. Importantly, this 
neutralization correlated to levels of both gp350-IgG and gp350-IgA antibodies in the 
plasma. In contrast, plasma was unable to neutralize EBV-2 infection and surprisingly 
enhanced infection of CBMCs. There was no difference in this enhancement effect for 
plasma from EBV-1 and EBV-2 infected infants and infants that were infected with a single 
EBV type or co-infected. When peripheral B-cells and T-cells were enriched separately from 
PBMCs, we observed neutralization of B-cell infection, but enhancement of T-cell infection. 
This suggests that enhancement was specific for T-cells, a cell type that is only able to be 
infected by EBV-2, in vitro. Furthermore, enhancement occurred with Kenyan infant plasma 
and North American adult plasma, suggesting no age or population dependent component to 
this effect.  
 Antibodies against gp350 have previously been shown to be most correlated to 
neutralization in a GFP-based neutralization assay with an EBV-1 virus [204]. More recently, 
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neutralization has been shown to be most correlated to specifically gp350-IgG1 antibodies 
using a qPCR based assay that was adapted for our study [205]. In this study, we also 
observed a significant correlation between neutralization of EBV-1 infection with gp350-IgG 
antibodies.  We have now shown a correlation between percent neutralization and plasma 
gp350-IgA antibodies. Suggesting that these antibodies play a role in EBV-1 neutralization. 
Our study, the first to use an EBV-2 strain for plasma neutralization, showed that 73% of the 
plasma samples enhanced infection, while a gp350-IgG monoclonal antibody was able to 
neutralize infection. There was a higher viral load in cells that were infected with virus 
incubated with plasma. However, it is unknown whether this enhancement is due to a higher 
frequency of infection or an increase in the number of virus copies per cell, which could 
suggest different mechanisms of enhancement.  
 Enhancement of infection with antibodies has been shown for EBV infection of 
epithelial cells. A gp350-IgA monoclonal antibody has the ability to enhance infection of 
polarized epithelial cells through the epithelial cell specific polymeric immunoglobulin 
receptor [93]. Importantly, this antibody still had the ability to block B-cell transformation. 
We observed our enhancement with T-cell infection, which do not express this epithelial cell 
specific Fc receptor. Furthermore, the enhancement effect observed here was not correlated 
with gp350-IgG or gp350-IgA antibodies. Though this does not completely rule out gp350 
antibodies, it suggests that enhancement of T-cell infection is not occurring through the same 
mechanism as epithelial cell enhancement. It is possible that a different Fc receptor, a 
difference class of antibody, or antibodies specific for a different EBV protein are mediating 
this effect. Furthermore, other constituents of human plasma could be causing this enhanced 
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infection of T-cells. The mechanism for this enhancement effect remains to be elucidated and 
should be explored further.  
 This effect has not been studied in vivo, however these results may have implications 
for an EBV vaccine. The most extensively studied EBV vaccine candidate is the viral gp350 
[220].  We have shown that even though antibodies against gp350 are present in plasma and 
are correlated to the in vitro neutralization of EBV-1, plasma enhances T-cell infection with 
EBV-2. Therefore, understanding what mediates this effect and if it is driven by gp350 
specific antibodies would be important in determining the efficacy of a gp350 vaccine 
against EBV-2. If mediated by antibodies against a different EBV antigen, those antigens 
may not be a viable vaccine candidate. However, if gp350 antibodies are mediating this 
effect, the proposed vaccine response may skew EBV-2 infection towards the T-cell 
compartment instead of the B-cell compartment. With that, there would likely be a higher 
risk of EBV associated T-cell diseases in EBV-2 infected individuals. It is crucial to the 
design of an efficacious EBV vaccine that EBV-2 be considered and clinical trials be done in 
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Figure 1. Comparison of the level gp350-IgG and gp350-IgA antibodies in plasma samples 
used for neutralization assays. A) Comparison of antibody levels in infants initially infected 
with EBV-1 or EBV-2. B) Comparison of antibody levels in plasma from infants infected 
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Figure 2. A) Neutralization of EBV-1 CBMC infection with Kenyan infant plasma. Data 
represented as % Neutralization for EBV-1 (uninhibited infection), 72A1 (anti-gp350 
neutralization control), and each individual infant plasma for the study. % Neutralization = [1 
- (EBV-2 + plasma EBV copies/µg β-actin DNA)/(EBV-2 only EBV copies/µg β-actin DNA) 
x 100%]. B) Comparison of the % neutralization for infants initially infected with EBV-1 
compared to those initially infected with EBV-2. C) % neutralization for single type infected 
infants compared to those that acquired a co-infection. Correlation of EBV-1 % 
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Figure 3. A) Neutralization of EBV-2 CBMC infection with Kenyan infant plasma. Data 
represented as % Neutralization for EBV-2 (uninhibited infection), 72A1 (anti-gp350 
neutralization control), and each individual infant plasma for this assay. % Neutralization = 
[1 - (EBV-2 + plasma EBV copies/µg β-actin DNA)/(EBV-2 only EBV copies/µg β-actin 
DNA) x 100%].  B) Comparison of the % neutralization for infants initially infected with 
EBV-1 compared to those initially infected with EBV-2. C) % neutralization for single type 
infected infants compared to those that acquired a co-infection. Correlation of EBV-1 % 
































































































































































Figure 4. Neutralization of EBV-2 infection of A) PBMCs, B) enriched B-cells, and C) 
enriched T-cells. Data represented as a % Neutralization for EBV-2 infection, % 
Neutralization = [1 - (EBV-2 + plasma EBV copies/µg β-actin DNA)/(EBV-2 only EBV 
copies/µg β-actin DNA) x 100%]. Cell purities for B-cell and T-cell fractions are also shown 






































































































































	   109	  
CHAPTER VI 
DISCUSSION 
 There were two major areas of focus for this dissertation. The primary focus was 
understanding the infection of T-cells with Epstein-Barr virus (EBV) type 2 (EBV-2), first by 
determining entry glycoprotein and receptors that are involved in infection and the early viral 
gene expression that occurs shortly after infection. In chapter II, I have shown that infection 
of T-cells with EBV-2 is mediated by the viral glycoprotein gp350 and its cellular receptor 
CD21. In chapter III, I have described the expression of viral genes within 24 hours of 
infection of T-cells. I have also observed the transfer of virion associated RNAs to T-cells 
and B-cells, within the first four hours of infection, with EBV-2 and both EBV type 1 (EBV-
1) and EBV-2, respectively.  
 The second goal of this dissertation was to understand the humoral immune response 
generated against EBV following asymptomatic infection in infants from a region of Kenya 
where both EBV-1 and EBV-2 are common. I have shown in Chapter IV a high frequency of 
co-infection with both EBV-1 and EBV-2 in Kenyan infants over the first three years of life. 
Most interestingly, infants who became co-infected had lower levels of anti-gp350 IgA 
antibodies in their serum, but no difference in anti-gp350 IgG. This suggests that the IgA 
response is important for protection against co-infection. In Chapter V, I have observed that 
plasma enhances infection of T-cells with EBV-2, while it neutralizes B-cell infection and 
infection with EBV-1. In this chapter, I will discuss these findings further and propose future 
studies to answer some remaining questions associated with this work.  
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EBV entry into T-cells 
 We have previously described the unique ability for EBV-2 to infect T-cells in vitro 
[47]. We have also shown the infection of peripheral T-cells with EBV-2 in healthy infants 
from Kenya, but not with EBV-1 [46]. This suggests that T-cell infection is unique to the 
biology of EBV-2. As this is a newly defined in vitro cellular tropism for EBV, one of the 
main questions that I sought to answer was what viral glycoprotein and cellular receptor 
EBV-2 uses to infect T-cells. The biggest contribution to the field of EBV in this dissertation 
is the identification of CD21 as a receptor for EBV-2 infection of T-cells, through 
interactions with the viral glycoprotein gp350. CD21 has been well established as a receptor 
that EBV uses to infect B-cells [84-87]. However, little is known about the expression and 
function of CD21, or complement receptor 2, on T-cells. Furthermore, the question still 
remains as to why only EBV-2 is able to use this receptor to infect T-cells, while it is able to 
be used by both EBV types to infect B-cells. 
I hypothesize that differences in the gp350 glycoprotein between EBV-1 and EBV-2 
allow for EBV-2 to infect T-cells. However, the structural consequences or differences in 
receptor interactions due to these amino acid differences have yet to be studied directly. I 
have observed differential antibody detection by flow cytometry of CD21 expressed by B-
cells and T-cells, but no differences in splicing of the mRNA transcript, suggesting potential 
post translational differences between the receptor expressed on either cell type. CD21 is also 
expressed at a lower level on T-cells compared to B-cells. Therefore, I hypothesize that 
gp350 from EBV-2 binds CD21 on T-cells with a higher affinity or avidity, allowing low 
levels of CD21 to mediate infection. This could be through the ability to bind a different 
form of CD21 on T-cells or the ability to activate CD21 to induce other cellular events, like 
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signaling or endocytosis, that allow for EBV-2 infection. Using purified gp350 protein from 
EBV-1 and EBV-2 to analyze the interaction affinity and avidity with CD21 would be useful 
to understand if the difference in gp350 plays a role. Furthermore, one could analyze the 
downstream signaling that occurs following ligation of CD21 on T-cells with the gp350 from 
EBV-1 and EBV-2. This may help us understand any differences in signaling that is required 
for infection. However, it is unlikely CD21 is the only receptor EBV-2 uses to infect T-cells.  
A higher percentage of T-cells express CD21 than are eventually infected with EBV-
2 even when infected at a high MOI. This suggests that an additional receptor, expressed on a 
smaller percentage of T-cells, is also required for infection of this cell type. A non-exclusive 
alternative is that there are post-entry restrictions to successful infection with EBV-2. This 
could be mediated by the specific cell type that is being infected or other intracellular factors. 
We are currently unsure as to what else is required for T-cell infection, in combination or 
downstream of entry with CD21. We hypothesize that an additional receptor is involved 
because all herpesviruses require the use of the core fusion machinery, made up of the viral 
glycoproteins gH, gL, and gB. However, a role for any of these glycoproteins in T-cell 
infection have yet to be defined. Therefore, it is likely that EBV-2 engages these 
glycoproteins through another receptor interaction to infect T-cells. For B-cells, this core 
fusion machinery is engaged by gp42, in a complex with gH and gL, interactions with HLA 
Class II [94-96]. For epithelial cell infection, gHgL directly binds αv integrins or the ephrin 
receptor A2 [115, 116, 118, 119]. These interactions induce fusion with the glycoprotein gB 
[91]. However, the engagement of these glycoproteins has yet to be defined for T-cells. Some 
peripheral T-cells do express HLA Class II, which could mediate infection. Using 
monoclonal antibodies specific for neutralization of EBV infection of B-cells, I did not 
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observe a role for gp42. However, I have recently identified some EBV type specific 
differences in this glycoprotein that have not been reported. It is unclear whether these 
differences would play a role in antibody neutralization. Therefore, a different approach to 
determine the role of this interaction would be to generate EBV-2 mutants deficient in these 
proteins. This approach would identify any role in T-cell infection. Unfortunately, these tools 
to generate these mutant viruses are currently only available for EBV-1 isolates and must be 
generated for EBV-2 in order to perform these experiments.   
CD21 function on T-cells 
In addition to the EBV glycoprotein gp350, CD21 is also the receptor for the 
complement component C3 fragments iC3b, C3dg, and C3d, the low affinity IgE receptor 
CD23, interferon alpha, and DNA [84, 296-299]. The expression and function of CD21 has 
been well defined on B-cells. CD21 exists in a complex with CD19, CD81, and Leu-13 or 
with CD35. It plays an important role as a B-cell co-receptor, enhancing B-cell receptor 
signaling following interactions with complement C3d coated antigens [300, 301]. 
Importantly, the majority of the signaling mediated by CD21 ligation is through CD19. Its 
expression and function has been characterized on follicular dendritic cells as well, in which 
it is thought to trap C3 bound antigens and hold them on the surface for interactions with 
germinal center B-cells [302]. However, little is known about the expression and role of this 
receptor on T-cells, as its expression is still under debate. Some studies have defined the 
expression of CD21 only on immature CD4+ CD8+ double positive thymocytes. Because of 
this, it has previously been thought to have a role in T-cell maturation.  However, there is a 
convincing body of evidence that suggests that it is expressed on peripheral, mature T-cells 
	   113	  
[245]. Here I have shown that it is expressed, though at a lower level than on B-cells, on both 
CD4+ and CD8+ peripheral T-cells.  
To our knowledge, mediating EBV-2 infection is the first confirmed functional role 
for CD21 on primary mature T-cells. As T-cells are presented with antigen derived peptides 
and not protein antigens, it is unlikely this receptor plays the same role on T-cells as B-cells. 
It has been hypothesized that CD21 acts to increase adherence of T-cells to target cells 
bearing C3 complement fragments [247]. It is possible, however, that like on follicular 
dendritic cells, it could act to hold antigens on the cell surface for interactions with B-cells. It 
would be important to study the role that the other CD21 ligands play in T-cell biology as 
well. For instance, one could hypothesize that CD21 ligation by interferon alpha could 
enhance the antiviral immune response by CD8+ T-cells. Understanding the function of 
CD21 could be crucial in understanding its contribution to the T-cell response. Importantly, 
defining the downstream effects of receptor ligation with gp350 could give us a better 
understanding of what is necessary for T-cell infection with EBV.  
CD21 has a very short intracellular domain and is not heavily involved in mediating 
signaling on its own. Therefore, the function of T-cell CD21 could be further understood by 
defining the protein complex CD21 is on T-cells. Only one study that has analyzed this 
observed CD21 as a stand-alone protein on T-cell lines and upon ligation there is recruitment 
of two additional proteins, only identified by molecular weight of 105 and 55 kD [256]. It 
would be critical for defining the function of CD21 on T-cells to identify the additional 
cellular proteins CD21 interacts with. Furthermore, the biological outcome of this ligation 
would be important to explore. This could be performed through defining downstream cell 
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signaling, changes in cellular gene expression, or alterations in T-cell phenotype that occur 
following CD21 ligation with its various ligands.  
Early events in EBV infection   
 Understanding the viral gene expression that leads to immortalization of B-cells in 
vitro has been an important model system to study EBV persistence in B-cells and 
lymphomagenesis. These studies have not been performed with EBV-2 or following T-cell 
infection before. In chapter III I have identified the transfer of virion associated RNAs during 
in vitro infection with both types of EBV. Virion associated RNAs are common amongst 
herpesviruses, but only one other study has described these for EBV following B-cell 
infection with EBV-1 [263]. Furthermore, that study showed a potential role for gene product 
of one of these RNAs, BNLF2a, to dampen the CD8+ T-cell response in vitro, even when de 
novo transcription was inhibited. Therefore, these RNAs potentially could have an important 
role in establishing EBV infection. I have shown that these RNAs are EBV type specific, as a 
different set of RNAs following B-cell infection with EBV-1 and EBV-2. Most importantly, 
we detected high levels of the viral lytic gene BZLF1 following EBV-1 infection, much 
greater than was detected following EBV-2 infection. Interestingly, the same proportion of 
RNAs were detected following EBV-2 infection of B-cells and T-cells. These early studies 
lead to a number of questions about the roles of these RNAs that should be explored further.  
 One important difference I have observed between EBV-1 and EBV-2 is the reduced 
transfer of the viral BZLF1 following B-cell infection with EBV-2. BZLF1, a major lytic 
transcription factor, is important for lytic reactivation and driving the prelatent phase of 
infection early after infection of B-cells. This prelatent phase has two main roles, the first to 
drive quiescent B-cells to proliferate and the second to prevent activation induced cell death. 
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Furthermore, lytic infection enhances transformation of B-cells [184]. EBV-2 has been well 
established to have a poor ability to transform B-cells [38, 41]. Interestingly, our group has 
previously observed, but not published, a reduced ability for EBV-2 to drive B-cell 
proliferation and a higher level of cell death in EBV-2 infected B-cell cultures, compared to 
EBV-1 (E. Wohlford and R. Rochford, unpublished observations). I hypothesize that the 
lower BZLF1expression following EBV-2 infection results in a reduced prelatent phase of 
infection and causes a diminished ability for EBV-2 to transform B-cells by inducing a lower 
amount of B-cell proliferation and increasing the rate of cell death. Inducing higher 
expression of BZLF1 early in B-cell infection with EBV-2 may rescue this phenotype and 
allow for a higher EBV-2 transformation efficiency. This could also be done by inducing 
expression of BZLF1 in virion producing cell-lines, so a higher amount of BZLF1 transcripts 
will be packaged in EBV-2 virions.  Furthermore, understanding what controls the expression 
and packaging of virion associated RNAs would be important to understand.  
  It has been shown with cytomegalovirus that the virion associated RNAs are 
packaged in the same proportion that they are expressed within the producing cell [274].  
Determining what is expressed in lytically reactivated EBV-1 and EBV-2 cell lines of and 
how this compares to what is detected in the EBV virion would be important to understand. 
Type specific differences in virion associated RNAs have been observed, therefore one could 
hypothesize that genes genetically distinct between EBV-1 and EBV-2 have a role in viral 
gene expression and packaging following reactivation. In order to test this hypothesis, one 
could measure the viral gene expression in EBV cell-lines following lytic reactivation. Using 
mutant viruses that have the EBV-1 gene inserted into an EBV-2 strain, one could determine 
which genes have a role in either expression or packaging of these transcripts. One likely 
	   116	  
candidate is the viral transcription factor, EBNA-2, which has been shown to have major 
functional differences between EBV-1 and EBV-2. Mutant viruses, like described above, 
have been used in previous studies [48, 49]. This would be important to understanding which 
viral genes have a role in what is expressed in the virion.   
I hypothesize that these transferred RNAs may not be solely associated with the EBV 
virion, but may also be produced and transferred via exosomes. We have previously shown 
that only about 7% of T-cells are infected in vitro, but a much higher percentage of cells that 
become activated and proliferate following infection of T-cell cultures [47]. This bystander 
effect could be a result of the transfer of viral RNAs and proteins within exosomes that cause 
some cell activation, in vitro. However, in order to understand the importance of these RNAs, 
we first need to understand the role that the proteins they encode have following expression 
in T-cells. This has been explored in depth in B-cells, but not in T-cells. The individual 
expression of viral genes within T-cell lines would be an important first step to understanding 
the function of these proteins in T-cells. Furthermore, using different techniques to isolate 
exosomes, one could analyze the viral genes and proteins that are expressed and their role in 
activating and inducing proliferation of T-cells cultures. If there is an impact on T-cells by 
exosomes, this could also play an important role in the EBV associated tumor 
microenvironment in altering the function of infiltrating T-cells.  
T-cell infection in EBV biology 
 The infection of T-cells with EBV-2, both in vitro and in healthy infants, is a recent 
novel finding that suggests EBV-2 infection of T-cells is a part of the biology of this virus, 
unique from EBV-1. Establishment of EBV latency and persistence has been modeled by B-
cell immortalization in vitro, but EBV-2 has a diminished ability to immortalize B-cells. 
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Importantly, EBV-2 does have the capacity to persist in the population. It is hypothesized 
that EBV-2 utilizes the infection of T-cells to contribute to the establishment of latency in 
vivo. The role of T-cells in establishment of latency is currently being pursued in humanized 
mouse model studies.  
 Interestingly, the majority of EBV associated T-cell diseases are from Asia, a highly 
EBV-1 prevalent region. Likely, while EBV-2 can infect and persist in T-cells in healthy 
individuals, EBV-1 infection may be pathogenic. There is no current model for EBV-1 
infection T-cells that will provide insight into whether this virus will transform T-cells in 
vitro. It is also unknown the risk factors that allow for EBV-1 infection of T-cells and cause 
disease. Potentially changes the level of CD21 or other receptor expression, either genetically 
or environmentally induced, may allow for infection with this type. Conversely, there is a 
lack of genetic information about the EBV-1 strains that have the ability to infect T-cells. 
Sequencing these strains may be crucial to discovering any unique attributes of these viruses 
that lead to T-cell diseases.  
 Infection of T-cells could also potentially alter T-cell function. We have shown in 
previous studies that the cytokine profile produced by T-cells in vitro is altered following 
infection with EBV-2 [47]. However, no other aspects of T-cell function have been examined 
following infection with EBV-2. A previous study that introduced LMP-2 into a T-cell line 
showed that it decreased TCR signaling by sequestering signaling molecules [28]. This, 
along with effects by other EBV proteins, could dampen the T-cell response and help to 
promote infection and persistence. However, the specific roles that EBV proteins play once 
expressed in T-cells have not been characterized yet. Importantly, it would be beneficial to 
determine the effects that different EBV genes have on the ability of the T-cell to function. 
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The in vitro infection of T-cells by EBV gives us a novel tool to understand any functional 
effect of infection. Understanding the outcome of EBV infection with EBV-2 and the 
changes to the T-cell biology is important to determining its role in T-cell diseases.  
 It is of great interest to EBV-2 biology to understand the context in which T-cells are 
infected and play a role in B-cell infection, in vivo. As previously described, Thorley–
Lawson has hypothesized that naïve B-cells are initially infected and EBV infection drives 
the B-cell through a germinal center and into a memory phenotype [19]. Later, upon 
differentiation of the latently infected memory B-cell into a plasma cell, the virus reactivates 
and progeny viruses can then re-infect the naïve B-cell pool. This mimics the process of 
antigen driven B-cell activation and differentiation. However, we must now consider the 
infection of T-cells in this life cycle for EBV-2. In the antigen mediated activation of B-cells 
there are stages in which B-cells interact with or are in close proximity to T-cells, outlined in 
figure 1. I hypothesize three of these scenarios that could mediate EBV infection of B-cells 
and T-cells from one cell-type to the other. First, upon initial activation of B-cells and T-
cells, the activated cells interact with one another through major histocompatibility complex 
+ peptide / T-cell receptor (TCR) and CD40/CD40 ligand (CD40L), outside the germinal 
center. It is unknown whether this activation state could drive reactivation of virus from 
either cell type, but this close contact could mediate viral infection. Furthermore, the close 
proximity to the B-cell follicle and T-cell zone could be an area of transfer of virus between 
these cell types.  Secondly, following proliferation and somatic hypermutation occurring in 
the dark zone of the germinal center, the B-cell will interact with the follicular helper T-cells 
in the light zone of the germinal center. This, as part of B-cell selection, is another point of 
contact between potentially infected or infectable B and T-cells. Third, one fate of this 
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process is differentiation of the antigen activated B-cell into a plasma cell, which has been 
shown to drive reactivation of EBV. Bordering the germinal center is the T-cell zone and the 
B-cell follicle. Reactivated virus from plasma cells has the potential to encounter T-cells that 
are susceptible to infection in this space as well. In order to understand this further, it would 
be important to describe which T-cell subsets, in the periphery and lymphoid tissue, are 
susceptible to EBV infection based on CD21 expression and in vitro infection assays. 
Furthermore, the location and cell type of infected T-cells within infected persons in vivo is 
important to understand. To this point, we have only shown the infection of peripheral CD3+ 
T-cells in vivo [46]. Furthermore, understanding which stimulations, including TCR 
engagement, allow for virus reactivation from a T-cell would help us understand the potential 
interactions that could produce progeny virions from infected T-cells for further B-cell and 
T-cell infection. This, in total, would allow us to better understand the role that T-cell has in 
establishing life-long latency with EBV-2.  
EBV antibody response and neutralization 
 The majority of infections with EBV are asymptomatic and result in infection for the 
life of the host. Asymptomatic infection is more likely earlier in life and early age of 
infection is associated with a higher risk for Burkitt’s lymphoma, a common EBV associated 
cancer in Africa [232]. The most crucial response is against the glycoprotein gp350, 
antibodies to which are most highly correlated with neutralizing antibodies against EBV-1 
[204]. Our study is the first to analyze the anti-gp350 antibody response in asymptomatic 
EBV infection. Furthermore, previous studies have not considered the EBV type the 
individual is infected with in the context of the antibody response. In Chapter IV, I described 
a cohort study of infants from Kenya that were monitored longitudinally over the first three 
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years of life. I observed a high frequency of co-infection with both EBV-1 and EBV-2. This 
co-infection corresponded with a lower level of anti-gp350 IgA antibodies, but not anti-
gp350 IgG. I hypothesize that IgA antibodies are important for protection against EBV. IgA 
antibodies are classically known to be important in mucosal areas, including the saliva. As 
EBV is most commonly transmitted via saliva, it would be important to understand how the 
IgA response in saliva compares to that of the peripheral blood. In future longitudinal studies, 
simultaneous sampling of saliva and peripheral blood to analyze the relationship between 
levels of anti-gp350 IgA antibodies in these different sites would be important to analyze, as 
I only measured IgA in plasma. This could be further correlated to the acquisition of co-
infection. 
 In Chapter V, I sought to determine the ability of plasma antibodies to neutralize 
infection with EBV-2, which has not been analyzed before. Using a qPCR based 
neutralization assay, I have shown that an enhancement of EBV-2 infection of CBMCs after 
incubation with plasma from Kenyan infants. However, this same plasma neutralized 
infection with EBV-1 using the same assay and neutralization correlated to both gp350 IgG 
and IgA antibodies. Upon further analysis, I found that this enhancement effect was specific 
for T-cell infection, as infection of B-cells was neutralized. Furthermore, this occurred with 
plasma from North American adults as well as Kenyan infants. The mechanism of this 
enhancement of T-cell infection is still unknown. Furthermore, it is still unclear if the 
increase in viral load is due to a higher frequency of infection, more copies of EBV per 
infected cell, or increased proliferation of infected cells. Enhancement of EBV infection of 
epithelial cells has been observed with anti-gp350 IgA antibodies and an epithelial cell 
specific Fc receptor [93]. Therefore, I hypothesize that this effect could be mediated by EBV 
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specific antibodies binding to Fc receptors that are specific for T-cells. However, further 
studies to determine the class and antigen specificity of these antibodies, as well as the 
receptor mediated this enhancement has not been explored yet. This effect could be mediated 
by other aspects of the serum, including complement mediated endocytosis of the antibody 
conjugated virions. In Chapter IV, the majority of infants that acquired co-infections were 
initially EBV-1 and subsequently had a secondary infection with EBV-2. It is unclear if this 
enhancement effect is occurring in vivo, however if secondary infection leads to a higher 
level of infection in T-cells, it would suggest these people may be at a higher risk of EBV 
associated T-cell diseases.  
Overall conclusions and implications 
 Overall, the studies presented in this dissertation have important implications for 
ongoing efforts to develop an EBV vaccine. EBV vaccine studies have primarily focused on 
using the viral gp350 as the candidate antigen, as antibodies against gp350 are associated 
with neutralization of B-cell infection [204]. However, no studies have yet taken into account 
the differences in EBV-2 gp350 or the fact that this strain is prevalent in many populations at 
a higher risk of EBV associated malignancies. Here I have reported important genetic 
differences in gp350 from EBV-1 and EBV-2 that should be considered in EBV vaccine 
design. I have also identified a high amount of variability in gp350 within EBV-1 isolates. 
This variability must be considered in developing a vaccine. Most importantly, little was 
known about the prevention of EBV associated T-cell diseases with a gp350 vaccine. In this 
report, I have shown that gp350 is important for EBV-2 infection of T-cells, supporting 
gp350 as a vaccine candidate.  
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I also analyzed the antibody response generated against early asymptomatic EBV 
infection in a high risk Burkitt’s lymphoma region. I observed lower levels of anti-gp350 IgA 
antibodies in infants that acquired a co-infection with a second EBV type. This work 
suggests that generating an IgA response against EBV may be critical in having an 
efficacious, sterilizing vaccine to prevent infection. However, the in vitro ability for 
antibodies to prevent EBV-2 infection of T-cells needs to be considered, as I have reported 
an enhancement effect on T-cell infection by EBV-2 with plasma from both EBV-1 and 
EBV-2 infected infants. It is still under investigation as to whether this effect is mediated by 
anti-gp350 antibodies, but it is important to understand before moving forward with an EBV 
vaccine. These aspects of infection and protection against EBV should be considered to 
develop an efficacious EBV vaccine that can prevent infection and ultimately reduce the 




















































Figure 1. Model of EBV-2 B-cell and T-cell infection during antigen mediated activation of B-cells. Figure adapted from introduction 
figure 2 identifying 3 potential areas of B-cell and T-cell infection. 1) Interaction between antigen activated B-cells and T-cells outside 
of the germinal center. 2) Interaction between B-cell and follicular helper T-cells in the light-zone of the germinal center during 
selection. 3) Reactivation of EBV from infected B-cell following differentiation into a plasma cell after germinal center selection. The 
virus could infect B-cells in the B-cell follicle and T-cells in the T-cell zone, proximal to the germinal center.  
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